CA2194374A1 - Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension - Google Patents
Pharmaceutical composition for the controlled release of moguisteine in a liquid suspensionInfo
- Publication number
- CA2194374A1 CA2194374A1 CA002194374A CA2194374A CA2194374A1 CA 2194374 A1 CA2194374 A1 CA 2194374A1 CA 002194374 A CA002194374 A CA 002194374A CA 2194374 A CA2194374 A CA 2194374A CA 2194374 A1 CA2194374 A1 CA 2194374A1
- Authority
- CA
- Canada
- Prior art keywords
- microgranules
- coatings
- moguisteine
- coating
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are compositions and dosage forms containing moguisteine and having controlled release properties, methods for using such compositions and dosage forms and methods for making them.
Description
2 ! 9 4 3 7 ~ ~ 112 PHARMACEUTICAL COMPOSITION FOR TIDE CONTROLLED RT~.T,l;,A~T~, OF MOGUISTE~E IN A LIQU~ SUSPENSION
Field of the Invention This invention involves controlled-release ,ul - ,.. - ~.. 1;~ A1 e.. ~ ;1;""~ in liquid dosage forms for the 'A/~ of "..,~". s:
na~6~ of the Invention S Moguisteine, (R,S) 2 [(2 .. _I.UAYI' y)methyl--3-~LhuAy~_fl~ul~yl-l-acetyl]-1,3-fhiq7(n1'-' , is a potent peripheral antitussive described in European patent EP 169,581.
Coughmg may be p1~ 1y relieved by either ~UAU~UI~,J~illg the neuronal coughing reflex or by reducing the amount or viscosity of fluids in the10 respiratory tract. Some _lliiLU~ of the frrst type, termed "meconic agents," act by centrally depre_sing coughing centers Codeine, one example of a meconic agent, is the most widely used antitussive, but has the d;~Ad~ L~ . of potentially causing addiction.
Thus, there is a need in the art for non-narcotic AIILiLu~
MognictPinP is an antitussive that is as potent as codeine, d~AL~vlll~illul,uh~
15 and zipripol, and 3 - 4 times more potent than (D,L)-v1v,ulu,ui~hle. ~ UV~L-IILIY~ it causes no addiction, and is better tolerated in high doses than codeine or d~A1 vlll~lllo-~ul-an as it induces sedation and a reduced lower tonus l~f-.~,u;~ is a racemic mixture of R(+) and S(-) .A.~18 ~ that have equivalent antitussive activity.
Studies on the ' of action of . :" ~ have shown that 20 .,.. ~ .r does not act via opioid receptors. Its site of action is peripheral, and it interacts with the so-called "rapidly adapfing irritanf receptors" (RARs) (Sampson, S.R., SUBSTITUTE SHEET (RULE 26~
WO96101628 2 1 9 4 3 74 l l~. c~l2 ~
et al., Adv F.rrll'-' Ri~ 281-290, 1979).
has the ~ of a prodrug. After oral or ~d~ ".u~o - ' only its active metabolite, (R,S)-2-[(..~,llw~-yl' y)methyl]-3-carboxy-acetyl]-1,3 i' ~ ~ ' - acid, c;m be found im biological fluids in ..,. ~ l,lr quantities.
S This active metabolite, however, is not suitable for oral r' ~ ~ ' " because it is absorbed at a rate five times slower than O ~ -The ~ ~g oral r ~ " known so far include tablets andpackages for 200-mg doses and a . ~ . 1 2 % - r ' The daily dose ranges from 100 to 800 mg, with the lower dosages being - ' ' to children.
One limitation on the use of ~ is its short half-life after ~ ' which, in humans, is less than one hour. Prior to the present invention, this meant that frequent ~ ;".. i.e., at least three to four times a day, was necessary to maintain constant therapeutic blood levels (Castoldi D. et al., (1990), Pi~armacol. Rcs., 22:102).
It is known that a , for multiple daily ~ ' adversely affects patient, , ' . Average: , ' for drugs taken once a day is 87 % but drops to 39% for drugs taken four times a day; therefore, ,r I '- that c~m be ~ ' twice daily or, even better, as a single daily dose, are ~i g ~~ '~ preferred (Kramer, J. A. et al., (1989), JAA~ :601.) A reduction in the number of doses can be achieved using slow-release dosage forms such as tablets, pellets or the like. For antitussive r, ' , however, liquid r, ' are the preferred dosage forms.
United States Patent No. 5,296,236 (hPr~in-~r, the "'236 patent") describes controlled-releaSe l ~ , for liquid r~ 1~tinn~, which 25 comprise O ' coated with several polymeric layers. In some of these a fraction of the active ingredient in the r~ ' is made available over time by release from the ~IPi~ , whereas a fraction is present in the imgredients and is biu~lv~ild~le ~ Iy after r' ' ' ~' The ~
described in the '236 patent, however, offer a suboptimal solution to particular problems 30 raised by liquid: ' ~ of "
A first s ' is the very unpleasant taste of , ~ . This makes the use of suspension ,r ~ '- or solutions, ' ' ', thus, it is not possible to mclude ' 1y b;u.lv~il~l~, . ~ ' O as in the '236 patent.
W096/01628 2 1 94374 ,~.,. 5/C~112 In order to obtain a O r, tbat can be easily suspended, the size of the ~ O ' after coating must be smaller than 500 ,um. Granules with sizes larger tban 500 ,um caumot be easily suspended as they tend to rapidly sediment, causing a n,)a l= " ".~ l of the active ingredient on ~ -i a, ~ Using5 llPiclo~ ' particles smaller than 500 ~Lm, however, increases the surface area,. ' ' '~" making it more difficult, as compared to tablets orpellets, to control release of the active imgredient and maintain it unchanged m time after of the The difficulty is even greater wlhen, as in the case of ~ , the lack Of ~ r drug increases the diffusion gradient amd speeds release of the dlug from10 the granules to the ~Ul~ milieu.
A second I ' im designing an a~ dosage form for O ~ using the teachmgs of the '236 patent is the relatively low meltmg point of the molecule, i.e., about 65~C (Drugs of the Future, (1991), 16:618). The problem arises because waxy lipophi]ic materials such as white beeswax, cetyl alcohol, stearyl alcohol, 15 glyceryl and the like (the use of which as coating materials is taught in the '236 patent), are I ' 1!, a lv ,, for coating O - - containing so as to effectively mask their bitter taste. These materials can either be solubilized and applied using .'' ~ ' solvents, which presents ~ and ~IVill ' I problems, or they cm be applied to llli.,l.o ' in the melted state 20 (Ph~rm. Res., (1990), 7:1119.) The use of .'' ' solvents, however, presents l6~ 1 and ellvil~ 1 problems. The latter approach i the use of heated . ' air to maintain the wax at a . above its melting pomt, since at lower i , waxes tend to solidify and are thus no longer usable as filming material. The use of relatively high I A ' 1i:., however, can liquify low-melting active 25 ingredients such as " ~ - and thus cause the coating procedure to fail, leavimg the use of chlorinated solvents (with its di~advall~6es) as the only altemative.
In summary, in the case of ~ ~6~ ' 5 ~ - amd drugs with similar properties, there is a need for controLW-release liquid r ~ ' that:
1) are easy to measnre amd to ingest;
2) have a time-dependent release that offsets the short half-life of the active ingredient and thus do not require multiple dosages;
3) exhibit ~li~L.,llJl.y stability after suspension in a liquid vehicle;
Field of the Invention This invention involves controlled-release ,ul - ,.. - ~.. 1;~ A1 e.. ~ ;1;""~ in liquid dosage forms for the 'A/~ of "..,~". s:
na~6~ of the Invention S Moguisteine, (R,S) 2 [(2 .. _I.UAYI' y)methyl--3-~LhuAy~_fl~ul~yl-l-acetyl]-1,3-fhiq7(n1'-' , is a potent peripheral antitussive described in European patent EP 169,581.
Coughmg may be p1~ 1y relieved by either ~UAU~UI~,J~illg the neuronal coughing reflex or by reducing the amount or viscosity of fluids in the10 respiratory tract. Some _lliiLU~ of the frrst type, termed "meconic agents," act by centrally depre_sing coughing centers Codeine, one example of a meconic agent, is the most widely used antitussive, but has the d;~Ad~ L~ . of potentially causing addiction.
Thus, there is a need in the art for non-narcotic AIILiLu~
MognictPinP is an antitussive that is as potent as codeine, d~AL~vlll~illul,uh~
15 and zipripol, and 3 - 4 times more potent than (D,L)-v1v,ulu,ui~hle. ~ UV~L-IILIY~ it causes no addiction, and is better tolerated in high doses than codeine or d~A1 vlll~lllo-~ul-an as it induces sedation and a reduced lower tonus l~f-.~,u;~ is a racemic mixture of R(+) and S(-) .A.~18 ~ that have equivalent antitussive activity.
Studies on the ' of action of . :" ~ have shown that 20 .,.. ~ .r does not act via opioid receptors. Its site of action is peripheral, and it interacts with the so-called "rapidly adapfing irritanf receptors" (RARs) (Sampson, S.R., SUBSTITUTE SHEET (RULE 26~
WO96101628 2 1 9 4 3 74 l l~. c~l2 ~
et al., Adv F.rrll'-' Ri~ 281-290, 1979).
has the ~ of a prodrug. After oral or ~d~ ".u~o - ' only its active metabolite, (R,S)-2-[(..~,llw~-yl' y)methyl]-3-carboxy-acetyl]-1,3 i' ~ ~ ' - acid, c;m be found im biological fluids in ..,. ~ l,lr quantities.
S This active metabolite, however, is not suitable for oral r' ~ ~ ' " because it is absorbed at a rate five times slower than O ~ -The ~ ~g oral r ~ " known so far include tablets andpackages for 200-mg doses and a . ~ . 1 2 % - r ' The daily dose ranges from 100 to 800 mg, with the lower dosages being - ' ' to children.
One limitation on the use of ~ is its short half-life after ~ ' which, in humans, is less than one hour. Prior to the present invention, this meant that frequent ~ ;".. i.e., at least three to four times a day, was necessary to maintain constant therapeutic blood levels (Castoldi D. et al., (1990), Pi~armacol. Rcs., 22:102).
It is known that a , for multiple daily ~ ' adversely affects patient, , ' . Average: , ' for drugs taken once a day is 87 % but drops to 39% for drugs taken four times a day; therefore, ,r I '- that c~m be ~ ' twice daily or, even better, as a single daily dose, are ~i g ~~ '~ preferred (Kramer, J. A. et al., (1989), JAA~ :601.) A reduction in the number of doses can be achieved using slow-release dosage forms such as tablets, pellets or the like. For antitussive r, ' , however, liquid r, ' are the preferred dosage forms.
United States Patent No. 5,296,236 (hPr~in-~r, the "'236 patent") describes controlled-releaSe l ~ , for liquid r~ 1~tinn~, which 25 comprise O ' coated with several polymeric layers. In some of these a fraction of the active ingredient in the r~ ' is made available over time by release from the ~IPi~ , whereas a fraction is present in the imgredients and is biu~lv~ild~le ~ Iy after r' ' ' ~' The ~
described in the '236 patent, however, offer a suboptimal solution to particular problems 30 raised by liquid: ' ~ of "
A first s ' is the very unpleasant taste of , ~ . This makes the use of suspension ,r ~ '- or solutions, ' ' ', thus, it is not possible to mclude ' 1y b;u.lv~il~l~, . ~ ' O as in the '236 patent.
W096/01628 2 1 94374 ,~.,. 5/C~112 In order to obtain a O r, tbat can be easily suspended, the size of the ~ O ' after coating must be smaller than 500 ,um. Granules with sizes larger tban 500 ,um caumot be easily suspended as they tend to rapidly sediment, causing a n,)a l= " ".~ l of the active ingredient on ~ -i a, ~ Using5 llPiclo~ ' particles smaller than 500 ~Lm, however, increases the surface area,. ' ' '~" making it more difficult, as compared to tablets orpellets, to control release of the active imgredient and maintain it unchanged m time after of the The difficulty is even greater wlhen, as in the case of ~ , the lack Of ~ r drug increases the diffusion gradient amd speeds release of the dlug from10 the granules to the ~Ul~ milieu.
A second I ' im designing an a~ dosage form for O ~ using the teachmgs of the '236 patent is the relatively low meltmg point of the molecule, i.e., about 65~C (Drugs of the Future, (1991), 16:618). The problem arises because waxy lipophi]ic materials such as white beeswax, cetyl alcohol, stearyl alcohol, 15 glyceryl and the like (the use of which as coating materials is taught in the '236 patent), are I ' 1!, a lv ,, for coating O - - containing so as to effectively mask their bitter taste. These materials can either be solubilized and applied using .'' ~ ' solvents, which presents ~ and ~IVill ' I problems, or they cm be applied to llli.,l.o ' in the melted state 20 (Ph~rm. Res., (1990), 7:1119.) The use of .'' ' solvents, however, presents l6~ 1 and ellvil~ 1 problems. The latter approach i the use of heated . ' air to maintain the wax at a . above its melting pomt, since at lower i , waxes tend to solidify and are thus no longer usable as filming material. The use of relatively high I A ' 1i:., however, can liquify low-melting active 25 ingredients such as " ~ - and thus cause the coating procedure to fail, leavimg the use of chlorinated solvents (with its di~advall~6es) as the only altemative.
In summary, in the case of ~ ~6~ ' 5 ~ - amd drugs with similar properties, there is a need for controLW-release liquid r ~ ' that:
1) are easy to measnre amd to ingest;
2) have a time-dependent release that offsets the short half-life of the active ingredient and thus do not require multiple dosages;
3) exhibit ~li~L.,llJl.y stability after suspension in a liquid vehicle;
4) are rr- ~ '1~ palatable to ensure patient, and wo 96101628 , ~ O 112 4 21 9~37~
S) do not require the use of chlorinated solvents or other e~ "y ~ ' ' or toxic materials.
It is thus an object of the present invention to provide a controlled-release pL~u~ 1 , in a liquid , capable of ensuring ' , lly S active blood levels of v (or, more accurately, its biologically active by one or two daily r ' ' ' ~' Preferably, the ~ " is ~ ..;, .J by excellent palatability and good stability with time after lC "' " with water.
It is a further object of the invention to provide a 1' I
.u~.l;..,.comprising , O lrc containing~ ~6~;'" "~ thatarecoatedwithatlease 10 tbree successive film layers that protect the I ~O from dissolution in the oral cavity (or upon 11 in a cncr.~ncinn) and promote its release in distal parts of the gv-oLlu~ voLil~l tract.
It is still a further object of the invention to provide a method for coating ~fiv~ contaiming low melting-point active ingredients such as O with lS waxes, while avoiding either melting the active ingredient or usmg cblorinated solvents.
Sumrnarv of the Invention It has now been found that a controlled-release IJI~ 1 dosage form suitable for the - ' of 1 lo in a liquid suspension can be achieved using 20 a " ,' ~, of , O ' contaming ~ as an active ingredient, which are coated with a succession of at least three coating layers comprising alternating h~d1ulul~
and lipophilic films and which are then formulated m a r~ ~ lly acceptable vehicle. The ~ r core, im addition to ,.,~ may contain at least one plasticizer, preferably puly viLyl~ v glycol, as well as other, optional, excipients, and have 25 sizes from 50 to 500 ~m and smooth surfaces suitable for coating with polymeric or waxy materials. The coatings prevent release of ~~, in the oral cavity amd ensure a subsequent ~ ' ' release profile of " im distal parts of the lUlllt~o~ tract and of the release profle over time. At least one of thecoatings should impart control release I-..- l .;Ji..~ to the O containing 30:, Optionally, the vehicle may comprise one or more of , "
! ' ' ' ," surfactant, v .. . ~ buffering, preserving and flavoring agents, as is withm the skill in the art. The dosage for n may be formulated as a liquid suspension im water (or im a mixture of water and water-miscible co-solvents) or as a dry powder to be WO 96/01628 }~ 't S12 ' with water and/or other solvents at the time of use.
In a preferred; ' ' t, O ' containing O ~ and pUIyDllljlvlrv glycol in a proportion of 0.5-l % by weight of the mixture receive one or two coatings comprismg cellulose acetate phthalate alternating with one or two coatmgs S comprising z waxy material such as, for example, mono-, di- and tri glyvvlidvs of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids, or, of the foregoing. Preferably, the waxy coating(s) is (are) applied in the melted state (i.e., without the use of solvents), by using heated uu.l~ Dvd air as a spray medium under conditions that do not melt the ~ ." ' core.
lOThe "",O.; ~ - of the present invention not only exhibit controlled-release . ~ that reduce the number of - ' ~ required to maintain consistent blood levels of L_ao ~ ' ~ , but also display excellent p~LLt~ y and stability upon l~ as a _ r ~ This is due to the fact that the active imgredient remains , ' within the coated lUivl~ o ' ' ~ - '- ' 1~/ following 15 imgestion, and thus passes easily amd quickly through the upper digestive tract without being tasted.
In another aspect, the present imvention ~ l a method for D~ , ' ' treatment of coughing, which comprises ~ ' ~ v effective amounts for treating coughing of the dosage form described above.
20In yet anotheraspect, the present invention provides a method rul ~IDIJ. ~ V
a palatable " ' release 1' ' dosage form for the - ' ~ of ~ in a liquid 1 which involves coating the aO ~ ~ contaiming lllivl~ O ' with the waxy materials in their melted state, using heated ~ l ' air as a spray medium. The method is applicable to coating any lllivluL ' containing amy 25 1 ny active ingredient, but is ~uti~uLuly applicable to ~, containing a lu.. ' g active imgredient.
Brief DP~rriDtion of the Dra~i~
Figure 1 is a graph illustrating the, of ,~ im the plasma of patients - ' ~ ~ ' either a standard 1 or the ." ' ~vlvllDD
r 1~rinn of the present invention.
Figure 2 is a graph illustrating a simulation of the blood levels of ~ that would result after two t~ of a standard suspension of O ~ ~ or a single ' ~ of the controlled-release wo 96101628 2 1 9 4 3 7 4 r~ a - ~12 of the present invention.
Detailed Description of the Invention All patents, patent A~ and literature references referred to herein 5 ~ hereby h.~ , ' by reference in their entirety. In the case of ~ ~ ~ the present ~ ;.... including defmitions, will control.
The ~ , of the present invention include a ~ of coated ,.. ;.. ~,~,.. ,l. c, which comprise ~ ~ ~ with one or more optional plasticizers and excipients, to which at least three successive layers of polymeric coatings are applied, at 10 least one of the coatings impar~ng controlled-release l I~A~A iS.~ to r ~ ~
containing the coated , ~ ' Three sequential coatings preferably comprise (i) cellulose acetate phthalate and plasticizer(s); (ii) one or more waxes; and (iii) cellulose acetate phthalate, .~ ly. (The coating (iu) can be identical to coating (i).) The coated 11Pi. ll " ' ~ then formulated for use im liquid These r ~ '- preserve the release .. 1 - A~ f~ of the dosage forms carried in them. They can be designed either as ready-to-use amd time-stable liquid with a shelf-life of at least two years, or as dry ~ ' that are lCi - ' with water when needed and then remain stable throughout the treatment period.
The present invention provides a controlled-release l~LAII
that includes: coated . IPC for the controlled release of ~ ~b -having sizes ranging from 50 to 500 ~m, preferably fiom 90 to 300 ~m, wnich ~
capable of remaining easily in suspension in a liquid for extended times. The ,, ' comprise:
a) ~ A core of, . .~ f: - -r., with one or more optional plasticizers and excipients, granulated imto 11li. 1l 0 1PC having sizes smaUer than 500 ~m, uniform surfaces, ~ lly spherical shapes, apparent densities of about 500 to 600 g/l andvery low friabilities, which ~ obtained by wet-kneading micronised ~ ~, (and plasticrzers and excipients if present), using water or a mixture of water and other solvents. This results in ~ ~O ' with no controlled-release properties prior to coating, which have physical proper ies that ensure 1~ ' ' ' - and uniform ~' ' -of subsequent coating layers.
b) A fi}st coatii~g having essentially hydrophilic .
1~ wo96101628 2 1 ~374 P~ 112 wbich isolates the Lllil..ll- g c) A second coating baving lipophilic, ~ on top of tbe first coating.
d) A third coating having hJ~U~II;IiC ~
5Also pNvided is a vebicle system for the above contNlled-release forms, comprising either a dry mixture of additives wbich can be combined with the ~ ~ ' for long-term drug storage, or an aqueous solution with optional additivesin which the ~ contairing ~ , ~ ' can be suspended and maintained in optimum release conditions for an extended period of time. Non '- g exaunples of the 10 additives are given below.
The elements tbat comprise the 1 ' ~' r~ of the present imvention are described below without limitation:
r~ ~
1~ -O ' with a high ~ ~ content and ~ ~ physical propelties (including size, shape, density and friability) that ensure uniform coating and ' ty are formed by wet-kneading a O ' mixture comprising ~ PNcedures for mixing may be as described in U.S. Patent No. 5,296,236, or as described in co-pending U.S. Patent-Application Serial No. 08/188,193 (the "'193 20 application", now aUowed).
In a preferred ~ t, poly~ L..~, glycol, (available as Carbowax from BASF Corp., Parsippany, NJ) is added to the ,~ ~ mixture before kneading, in an amount from about 0.3 to about 1%, preferably 0.6%, relative to the weight of the mixture, to promote an optimum spherical shape and surface of 25 the, ~ ~uO.~ to be coated. PEG is highly soluble in water (i.e., at, higher than 10% W/V) and thus facilitates wettmg of ~O ~ ~ , which is relativelyinsoluble in aqueous fluids. PEG was ~u~ ...oly found to promote the formation of LUi~,ll ,, ' spherical shapes even when present at, Iower than I %. In practicing the present invention, any PEG 1..~ containing polymers of molecular 30 weight from 200 to 8000 may be used, preferably from 5000 to 7000, and most preferably PEG 6000 (CARBOWAX~ 6000).
The O containing O ~ cores may also contain optional excipients, including fillers and binders, selected without limitation from those commonly Zl 94374 ~vo 96/01628 ~ l12 ~1 used in wet mixing, such as lactose, dibasic calcium phosphate, I..ik.l~J~,lJ ~lalline cellulose, starch, talc, sugars, polyvillyl~ylll ' ' , gelatin, a copolymer Of POIYVi1IJIYY ' ' and vinyl acetate, and the like. Preferably, the I O 1P~ contain lactose as a filler (lactose content is im the range 10-50% by weight) and polyv ylL~y~ LJm as a binder S (PVP content is in the range 5-20% by weight).
Procedures for mixing may be as described in the '236 patent, or as described in the 193 A~ The n~ixing liquid used for wet-V ' for example in high-speed rnixer ~ ' can be water; or a solvent t~at is miscible with water, such as, for example, ethyl alcohol or other alcohols used in the l' 10 industry, or mixtures of water and at least one other solvent thereof.
The operating conditions for the kneading and grn~lqtinn steps are those that result in a , O ~ with optimum physical, ~ . r~ that enable the deposition of an effective coating. For example, the ' 193 application describes acceptable and preferred ranges for process parameters usmg a fast mixer and rnill, e.g., the relative 15 proportion of mixing fluid added to the dry ~ ' mixture; the rate at which the fluid is sprayed; the spray pressure; the kneading time; and the ' . ' mixer andmill speeds. The kneaded mixture is then dried to a residual humidity of 1-10%, preferably 5-8 %, and screened to select particles of the required size range. Finally, the resulting . O ' is evaluated with respect to the following properties: particle size 20 ~ ;n ~ density (aerated, packed, and apparent), Carr index ( , ' "~/), and angle of repose. Finally, as described below, the granulate is coated with films of different, ~g~
Coating the s,, containing ~ O ' in accordance with the present invention serves at least two purposes. First, the coatings prevent the release of ,, ~ in the oral cavity, thereby masking the bitter taste of . O and increasing the palatability of liquid r ~ '' comprising O ~ Second, the coatings ensure a ~ ~ " ' release profile of " delivery after it reaches the 30 gastric and intestinal milieus. Coated ~ ,O.-: s :- - containing ~, ' should comprise a pH-resistant (i.e., enteric) coating layer but it need not be the frst one applied of the at least three coatings.
~, contath~ing ~ uo.~ ate thus coated with at least three alternating WO96/01628 21 9~374 ~ 112 hydrophilic and L~,-, coating layers as descnbed below. Preferably, the last-applied coating should be Ly~L~r' "- to aid solvation amd -r ' The preferred coating technique for all of the coating below, is the fluid-bed technique in accordance with the Wuster technology tJones, D., Dr~g Dev.lndus. Pharm. 20:3175-3206, 1994).
5Substances suitable for the frrst type of coating imclude without limitation hydrophilic substances such as, for example, derivatives of cellulose (such as cellulose acetate phthalate, Lydlu~y,ulu,uy- .~1 cellulose phthalate, ethyl cellulose, carboxyl methyl cellulose acetate, and the Lke) and acrylic polymers (such as co-polymers of esters of ' yllc and acrylic acid, methyl ~' and the like). Preferably, cellulose 10 acetate phthalate or h.~dlu~yAululuyL~ rl~llulose phthalate are used. These polymers may be optionally mrb~ed with ~ such as diethyl phthalate, dibutyl sebacate, vegetable oils and the like that are well-known in controlled-release r ~ ,-Substances suitable for the second type of coating layer, which has a lipophilic nature, imclude without limitation fatty substmces such as mono-, di- and 15 tri-glycerides of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids and . ~ thereof. These coatings can be applied with the help of, ~ 1 ' solvents. Preferably, however, the waxes are applied im the melted state, with no use of solvents. Since O - has a low melting point (65~C), it is important touse conditions that allow coating without melting the ~ in the core. It has now 20 been found that the use of a coaxial nozle, wherein the spray fluid is: ~ air that is rr~ y heated to maintain the waxes constantly in the liquid state, as well ase of the 1 1 ~ of the coating chamber ~ulrlch.~lly warm, allows the waxes to coat a Lr " ~ -containing IIIL,I~ 0 ' without melting the ,.~ . rlr The same substances that make up the first coatmg layer may also be used 25 for the third coating layer. It is in any event preferred that the last-applied coating be LylLu~h;lic, as stated above.
Vehicle In practicing the present invention, the O -containing 30 ~- - " ' coated according to the above pl~ ~ s, is combined with a vehicle toform either a dry mixture that cam be suspended e~empore when needed, or a ready-to-use liquid !
For addition to the coated , O ~ comprising ~ "- ' release WO96/01628 2 i 9~jf 374 r~ ~t~12 dosage forms of , , the of the vehicle can include without limitation:
- suspending or structuring agents such as cellulose esters, ialline cellulose, algimc acid derivatives, and ~l~vh~ " ' dl,liV~liiV~
S - surfactants (preferably anionic or nonionic) such as Span 20, Span 80, Tween 20, and sodium lauryl sulfate;
- sugars such as sucrose, sorbitol, xylitol, dextrose and the like;
- buffering substances such as citric acid and sodium citrate, glycime and hydll 1 - acid, sodium phosphate, and potassium phosphate;
- ~ V~ and 1 ~ agents such as esters of p h~dlv,.~ .~.Jic acid; and - various flavormgs and sweeteners commonly used in l ' It will be understood that the specific , of the ' ' with respect to both nature and amount of added ~ ' will vary according to the 15 particular q~ nn See, e.g., Wade and Weller, eds., Hand~ook~f Mh.~ 7 E~Gipients (2d.Ed.), The r~ 1 Press, London, 1994.
In addition to the above i..l,l. ' the ready-to-use r 1 also comprises water, or mixtnres of water and pl~ acceptable water-miscible co-solvents known im the alt such as glycols, alcohols and glycerol.
20The ~ n~;lin~ of the present invention lend themselves to different forms, including, for inst~mce, (i) multi-dose granular ' ' whereim dose flexibility is obtained by measuring different amounts of granules to be re-suspended when needed; (ii) accurately ' ' single-dose r ~ " im the form of sachets;
(iu) bottles with reservoir caps for offhand 1~ and other forms known to the 25aIt. E~or pediatric use, the present invention also ~ , II,., ~ ~i" comprisimg' drops (e.g., drops containing 10% wlv O which works out to about S mg of active ingredient per drop) in which the granules contaming " are suspended.
30 Th~utic Ad The 1 - 1 r ~ " of the present invention are intended to deliver effective amounts of ~, in one or two daily: ~ An "effective amount" of ,. .c ..; is one that provides relief from coughing im a patient.
WO96/01628 2 1 943 74 P~ 112 It wiU be ' ~~ that an effective amount can be delivered at a given time by imgestion of a single dose or a plurality of doses. TypicaUy, a daily dose of ~g ~
effective in preventing and/or treating coughing is from about S to about 15 mg/kg weight of the patient. The average dose is 9 mg/kg. Thus, r ~ ~ ~ ' ' of an antitussiveS effective amount of O ~ ~ may involve once or twice daily - ' ~ ~ of about2 to about 30 ml and preferably 10 ml of a final & ~ (prepared as described in Example 8A below) containing 30 mg/ml - " ~ -The benefits of the present invention include a, ' ' '- , u._mel-t in patient . , ' , based on both a reduction in the number of daily doses and good 10 palatability. Additional benefits are anticipated in pediat~ic practice due to the ease of - ' ~ and swaUowing. r..11h~,11-~u1~;, a better therapeutic response is likely to result, since, im a preferred, ' ' t, the ~ ' permits, ~u~ 1 ;".. of dosage as a function of need simply by measuring the required suspension volumes.
The examples provided below are intended to more fully describe preferred 15 ' ' of the invention and to ~' its advantages and ~ y, without limiting its scope.
EXA~ l~ of a r~-~uistei,~e ~\T ~ " ulate A mixture made up of 79 % (w/w) ~ ~ -, 10 % (w/w) 20 pol~ I,uy11oLJu11e (PVP K30) and 10 % (w/w) 450-mesh lactose was mixed in a Diosna P25 mixer-granulator for 10 minutes. A 1% (w/w) of PEG 6000 was added as an aqueous solution to the stirred mrxture at a rate of 25 ml/min using a 0.8 mm nozzle at a pressure of 2 bars. During the wetting step the mixer speed was 175 rpm and the speed of the miU was 3000 rpm. The time required to add the solution was 20 minutes. After 25 wetting, the kneading and rounding step was performed by l~ , mixer and miU
speeds at a constant rate for 15 minutes. The ~ , O ' so obtained was dried in an artificial ., ' imcubator and then sieved through a 225-mesh/cm2 screen until a ~ , ~, ' with a granule size 1'- ' ranging from 90 to 300 ,um, a spheroidal shape, a tapped density of 0.593 g/ml, and a real density of 1.36 g/ml was obtained.
l~AM~-F 2:
Amixtnremadeupof79.4% (w/w) ~ ~ ,10% (w/w)lactose, 10%
(w/w) PVP K30 and 0.6% PEG 6000 was mixed and kneaded as in Example 1.
wo96101628 2 1 9~374 ~ 1/~ .12 ~
F~AMPLE 3: -A mixture made up of 79.4% (w/w) ,...,c,. ~.t. ' , 10% (W/W) 450-mesh lactose, 10% (w/w) PVPK30 and 0.6% (w/w) PEG 6000 was wetted with 500 ml of water, which was added at a rate of 25 ml/min over 15 minutes. PEG was added as a 5 %
S solution as in Example I above. The speed of the mixer was 175 rpm and that of the mill 3000 rpm. The O ' obtained after drying had 4% residual moisture, an untapped density of 0.548 g/ml, a tapped density of 0.669 g/ml, a Carr index of 18.08%
and an actual density of 1.38 g/ml. The above parameters are described in detail in Ellis Eorwood, Ed., (1988), M~,..~eu~lcal r,~fiu, 7~~'?n, pp. 209-214, Chichester, 10 England; and in Advances in r~ 7 Science; 2:181-220, 1967. Individualparticles within the ~g ' thus obtained exhibited a particular surface c due to the presence of PEG 6000.
EXAMPLE 4: E9rst ~51m Laver (Cellulose Acetate Phthalate) Two kg of the ~ " 1 prepared in accord,mce with Example 3 were stirred for 1 minute im a Glatt GPCG3 (Glad, GmbH, Buizen Lorrach, Germany) fluidizer into which air heated at a , of 40 to 45~C was blown at a rate of 40 m3/hour.
The granulate was sprayed at a pressure of 2 bars and a rate of 10 to 13 g/min with 400 ml of a solution havimg the following weight per-cent Cellulose acetate phthalate 4 %
Diethyl phthalate 1 %
Acetone 71 %
Isopropyl alcohol 24%
h'.~AlVlPLE 5: Second E91m Laver (Waxes) A solution having the following weight per-cent: . was prepared:
Glyceryl t~ 4.50%
White beeswax 0.40%
Cetyl alcohol 0.05%
Stearyl alcohol 0.05 %
Chloroform 90.60%
Metbanol 4 40%
~ WO 96/01628 r~ 12 1.152 g of this solution were applied to 2000 g of the ., previously coated with a first layer as described im l~xample 4. The identical operating conditions as in Example 4 for apply the second layer were used in this case.
5 F.~Al\ IPT h 6 A mixture of waxes was prepared havimg the following weight per-cent Glyceryl 90%
White beeswax 8%
Cetyl alcohol 1%
Stearyl alcohol 1%
This mixture was applied in the melted state to O ' previously coated with a first layer as described in Example 4. In this case, the waxes were first 15 melted by incubation at a ~ u~ of about 110~C. They were then sprayed in the melted state at a i ~ of about 80~C, onto 2 kg of O ~ This was ~rrr q~r~ ~ ~ usimg air pre-heated at a i . ~ of 125 ~C and: . ~Dll~ to a pressure of 3 bars using a coaxial no77:le which mixes the melted wax and the hot: ll ~ air.
The spraying step was performed with a 7" Wurster insert in a Glatt apparatus. Wax amounts equivalent to 3.8% by weight (relative to the weight of the uncoated ''1. ~ ) were sprayed at a rate of about 1.5 g/min.
~MP~li 7: TllirdF~lmLavçr The same ingredients and procedures described in Example 4 for depositing the first coating layer were used for the final coating layer ~AMPT F 8: r~ ' F ' 1~ r~ ~çinç
4 A) ~ in multi~ose bottles A " ~ , prepared as described in Example 3 and coated witn 30 three successive layers as described in Example 4, 5 and 7, was added to a final proportionofl2.5% (w/w)toamixturecontaining6.2%~ 1u~ 11inecellulose,0.8%
sodium ~IWAY '-,yk 1l ' , 0.5% sodium citrate, 0.8% citric acid, 0.2%
m~ , 0.05% ~lu~ ~ab~l., 2% tragacanth, 0.05% Span 20 surfactant. 0.2%
~WO96/01628 219~374 r~l,~ c 112 ~
ùly~ilu~l~ 0.01% glycamil, 0.25% orange-grapefruit flavor amd powdered sugar to 100%. tThe above values all represent ~ by weight.) By adding 80 g of water to 33 g of suspension mixture, a 100 ml suspension contau~ing 30 mg/ml of , O was obtained. The parabens in the foregoing ~ l serve as 5 ,u.~ aliv~ I,uuly~ilu~ule is an anti-foam agent.
B) .S A ~ in ~ ,lc ~1l packages 3.3 g of a suspension mrxture prepared as described at paragraph A were divided into individual aliquots, each comprising a single 300 mg dose of c , in paper/aluminum/polythene packages. The contents of each package may be rc s~ Pn~10 in half a glass of water C) ~5', ~. in. ~'~ ' bottles 1.25 g of a ~ .c ' , prepared as described in Example 3 and coated ~u~,c~ ,ly as described in Example 4, 5 and 7, were placed in the reservoir cap of a single-dose bottle (Bormioli Metalplast, Parma, Italy) and kept separate from the liquid 15 contained in the single-dose bottle. The ~ , of the single dose was 3,500 mg of 70% sorbitol, 15 mg of,u~.wu~le l flavors, 15 mg of citric acid, 10 mg of sodium benzoate, and purified water to 8 ml. Before use, the contents of the reservoir cap are put in contact with the liquid in the bottle by pressing the reservoir cap. Each bottle contains 300 mg of c as a smglé-dose ~ , D) p. 5 ~ -To obtain 100 ml of a ready-to-use ~n~lPn~i~m, 4 g of a ~Il;ul.c ' that had been prepared as described in Example 3 and coated with three successive layers as described in Examples 4, 5, and 6, I~",u~~ ly, were added slowly and under vacuum to a liquid vehicle having the followimg, cellulose (.ui. l~ ,Ldlline) 0.85 g sodium ~ub~Ayl..~,ll.yh.llulose 0.15 sodium lauryl sulfate 0.10 potassium sorbate 0.15 sorbitol (70% solution) 67.50 glycerin 11.80 xanthan gum 0.12 titanium dioxide 0.50 _ _ _ ~Vo96/01628 2 1 9 4 3 7 4 I_ ~ 112 ~- .ylyolyi~;loxane 0.10 ci~ic acid ' y.' 0.10 mannitol 0.40 flavor 0. 15 purified water to 100 ml This solution requires no further ~ but can be used by the patient directly as is.
EXAMP~E 9: In Vitro Te~j~ of R.qlf.Ier Release of l ~ from coated ~ ~ "' prepared as described in Examples 3, 4, 5 and 7 was tested UsiDg ~pparatus II (paddle) described in the United States rl,~ ul,or ~ Ed. XX~, operating at 75 rpm at 37~C. 900 ml of dissolution medium were used for 300 mg of 1 O Por the first hour, the dissolution medium was 0.1 N MCl and, from the second to the twelfth hours, phosphate buffer at pH 7.4.
15 The amount of active ingredient released into solution was determined ~Y~I~r11y by measuring _ ~ of the solution at 275 ~m. The p~of active ingredient released in time (hours) by a ~ ,,, ' were as follows: 21% (1 hour), 46% (2 hours), 78% (4 hours), 93% (8 hours) and 98% (12 hours).
EXAMPLE lO: ~in of 1~ ' ~akili.tv wit~ Time A) The stability of a controlled-release suspension prepared as described in Example 8, Section A was ~' ' in the following manner. The coated , ~ ' and drug vehicle component mixture was 1~ ' in water initially, 25 at 3 months, and 6 months, and the in virro release of ~.r~ r~ was tested using the procedure described in Example 9. The results are shown in Table 1:
WO 96/01628 2 1 9 4 3 7 4 I~ 12 Stability conditions % of ~ ~ - released lh 2h 4h 8h 12h Initial 22 50 77 94 95 25~C, 3 months 21 52 82 97 98 25~C, 6 months 22 52 80 95 96 35~C, 6 months 22 50 76 89 90 These data ~ that the release profile for " - was essentially unchanged even for samples that were 1~~ after storage for 6 months at 35~C.
In amother test involving an identical flqtitm the dissolution profile of the suspension was evaluated 15 days after 1lwith water. The results are shown in Table 2.
Dissolution conditions - % of m~ ~ ~ released lh 2h 4h 8h 12h Initial 22 50 77 94 95 After 15 days 21 48 79 93 95 The dissolution profile of ~, was unchanged even 15 days after 1~ with water, thus ensuring good dissolution stability throughout a typical 25 course of therapy.
B) The stability of a controlled release ready-to-use suspension prepared as described in Example 8, Section D was determined as described above by assessing the percentage of ~ ~ release initially amd after 18 months. The results are shown in Table 3.
W0961û1628 2 i ~4 3 74 I~_l/~. .l 112 Dissolution % of,, . ': released lh 2h 4h 8h 12h Initial 18 48 76 97 100 After 18 montns19 50 76 93 98 In tbis ready-to-use r 1qfinn, the dissolution profile of ,... ,O..;- s --r was unchanged after 18 months; tbis is ~li "y due to the relatively low proportion of water in the r ~ ,UI~ ' ly 30%) 10 EXAMI~J,E 11 Phvsica~ r~ r Water up to 100 ml was added to 33 g of a suspension prepared as described im Example 8. The following paTameters were then measured: 1) S. ' F, which is the ratio between the height of the sediment the height of a suspension that had been stirred allowed to st for 3 days; 2) pEI; 3) viscosity, as 15 measured with a Brookfield DVII apparatus; 4) density. The results were as follows:
F = 0.6, p~I = 4.3, Viscosity (cps) = 226, and Density (g/ml) = 1.1.
EXAMPLE 12 Bi ' ' ~ ~
A single-dose kinetic study using the ~ ' of the present invention 20 was conducted to evaluate, ,~,.; :--- b;~ v~;ld~ilily. Six healthy volunteers received a single 10 ml dose of a controlled-release bquid rl ' (equivalent to 300 mg of ) prepared as described in Example 8. Blood samples were taken at different times, and the O - plasma: (evaluated as an acid) was determined by an HPLC method. In a second t}ial, the volunteers were r ' ' ' ' c;d a dose of a uu"v, 1 2% suspension equivalent to 200 mg of ~L.Table 4 compares the main ~l - . ", ~ k .... I ;r parameters obtained fiom the two ~ Mlo ' Cmax Tmax AUC
(~g/ml) h (~g h/ml) C.R suspension 1.79 2.83 7.05 Standard suspension3.05 0.73 4.01 wo 96/01628 ~ 1 ~4 3 7 4 P~ll~ 5'~ ~ 112 C~"" = (Pea~the highest plasma ~~ - ' the drug reaches after the .~
T~"l = (Time ~" ) the time necessary to reach the C~ value;
AUCo ~ = (Area under the curve) the total area of the time-. ' profile and 5represents a measure of the b;u~v~ildlJ;liLy.
These data indicate that in the controlled-release r ~ '- of the present invention:
10(a) T,,,,~ is delayed and C",~" is reduced relative to the CUIIV~
~ . as expected for a controlled-release r~ -(b) The half-life (tl~2) amd the calculated mean residual time (MRT) are increased three-fold relative to the w..~,...iu..al , ' , and (c) The AUC and, aCWld- .,1~l, the relative b;u~v~ b;lily are lS similar to the ~,ullv~ I A
These data indicate that the suspension prepared according to the present invention exhibits the properties of a controlled release ,r ~ '- with excellent ~;U~V.~ y.
Figure I shows these results after li7~ n of a~ ~ ~ blood levels 20 for the difference between the initial ~ ~ ~ dose in the controlled-release and cu..v, ~ r, ~ The graph shows dose values (L-l) on the ordinates and time on the abscissas. The data indicate that the ~' " of ~ ~ according to the present invention permits the initial peak effect to be avoided and the number of daily dosages to be reduced, while ensuring sd~r~Lul~ therapeutic 25 blood levels of O ~ ~ over an extended time.
Figure 2 shows a simulation of blood levels of, .,~ s after two -' ' of a standard suspension or a single ~ ' ~ of the controlled-release c~ pnc~ e ~ release suspension avoids the initial peak effect (thus ~ associated side effects) observed with the standard A ' r, c;~
30 the controlled-release suspension can be used in a twice-daily ' ' ~ ' ' regimen, versus four times daily with the standard
S) do not require the use of chlorinated solvents or other e~ "y ~ ' ' or toxic materials.
It is thus an object of the present invention to provide a controlled-release pL~u~ 1 , in a liquid , capable of ensuring ' , lly S active blood levels of v (or, more accurately, its biologically active by one or two daily r ' ' ' ~' Preferably, the ~ " is ~ ..;, .J by excellent palatability and good stability with time after lC "' " with water.
It is a further object of the invention to provide a 1' I
.u~.l;..,.comprising , O lrc containing~ ~6~;'" "~ thatarecoatedwithatlease 10 tbree successive film layers that protect the I ~O from dissolution in the oral cavity (or upon 11 in a cncr.~ncinn) and promote its release in distal parts of the gv-oLlu~ voLil~l tract.
It is still a further object of the invention to provide a method for coating ~fiv~ contaiming low melting-point active ingredients such as O with lS waxes, while avoiding either melting the active ingredient or usmg cblorinated solvents.
Sumrnarv of the Invention It has now been found that a controlled-release IJI~ 1 dosage form suitable for the - ' of 1 lo in a liquid suspension can be achieved using 20 a " ,' ~, of , O ' contaming ~ as an active ingredient, which are coated with a succession of at least three coating layers comprising alternating h~d1ulul~
and lipophilic films and which are then formulated m a r~ ~ lly acceptable vehicle. The ~ r core, im addition to ,.,~ may contain at least one plasticizer, preferably puly viLyl~ v glycol, as well as other, optional, excipients, and have 25 sizes from 50 to 500 ~m and smooth surfaces suitable for coating with polymeric or waxy materials. The coatings prevent release of ~~, in the oral cavity amd ensure a subsequent ~ ' ' release profile of " im distal parts of the lUlllt~o~ tract and of the release profle over time. At least one of thecoatings should impart control release I-..- l .;Ji..~ to the O containing 30:, Optionally, the vehicle may comprise one or more of , "
! ' ' ' ," surfactant, v .. . ~ buffering, preserving and flavoring agents, as is withm the skill in the art. The dosage for n may be formulated as a liquid suspension im water (or im a mixture of water and water-miscible co-solvents) or as a dry powder to be WO 96/01628 }~ 't S12 ' with water and/or other solvents at the time of use.
In a preferred; ' ' t, O ' containing O ~ and pUIyDllljlvlrv glycol in a proportion of 0.5-l % by weight of the mixture receive one or two coatings comprismg cellulose acetate phthalate alternating with one or two coatmgs S comprising z waxy material such as, for example, mono-, di- and tri glyvvlidvs of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids, or, of the foregoing. Preferably, the waxy coating(s) is (are) applied in the melted state (i.e., without the use of solvents), by using heated uu.l~ Dvd air as a spray medium under conditions that do not melt the ~ ." ' core.
lOThe "",O.; ~ - of the present invention not only exhibit controlled-release . ~ that reduce the number of - ' ~ required to maintain consistent blood levels of L_ao ~ ' ~ , but also display excellent p~LLt~ y and stability upon l~ as a _ r ~ This is due to the fact that the active imgredient remains , ' within the coated lUivl~ o ' ' ~ - '- ' 1~/ following 15 imgestion, and thus passes easily amd quickly through the upper digestive tract without being tasted.
In another aspect, the present imvention ~ l a method for D~ , ' ' treatment of coughing, which comprises ~ ' ~ v effective amounts for treating coughing of the dosage form described above.
20In yet anotheraspect, the present invention provides a method rul ~IDIJ. ~ V
a palatable " ' release 1' ' dosage form for the - ' ~ of ~ in a liquid 1 which involves coating the aO ~ ~ contaiming lllivl~ O ' with the waxy materials in their melted state, using heated ~ l ' air as a spray medium. The method is applicable to coating any lllivluL ' containing amy 25 1 ny active ingredient, but is ~uti~uLuly applicable to ~, containing a lu.. ' g active imgredient.
Brief DP~rriDtion of the Dra~i~
Figure 1 is a graph illustrating the, of ,~ im the plasma of patients - ' ~ ~ ' either a standard 1 or the ." ' ~vlvllDD
r 1~rinn of the present invention.
Figure 2 is a graph illustrating a simulation of the blood levels of ~ that would result after two t~ of a standard suspension of O ~ ~ or a single ' ~ of the controlled-release wo 96101628 2 1 9 4 3 7 4 r~ a - ~12 of the present invention.
Detailed Description of the Invention All patents, patent A~ and literature references referred to herein 5 ~ hereby h.~ , ' by reference in their entirety. In the case of ~ ~ ~ the present ~ ;.... including defmitions, will control.
The ~ , of the present invention include a ~ of coated ,.. ;.. ~,~,.. ,l. c, which comprise ~ ~ ~ with one or more optional plasticizers and excipients, to which at least three successive layers of polymeric coatings are applied, at 10 least one of the coatings impar~ng controlled-release l I~A~A iS.~ to r ~ ~
containing the coated , ~ ' Three sequential coatings preferably comprise (i) cellulose acetate phthalate and plasticizer(s); (ii) one or more waxes; and (iii) cellulose acetate phthalate, .~ ly. (The coating (iu) can be identical to coating (i).) The coated 11Pi. ll " ' ~ then formulated for use im liquid These r ~ '- preserve the release .. 1 - A~ f~ of the dosage forms carried in them. They can be designed either as ready-to-use amd time-stable liquid with a shelf-life of at least two years, or as dry ~ ' that are lCi - ' with water when needed and then remain stable throughout the treatment period.
The present invention provides a controlled-release l~LAII
that includes: coated . IPC for the controlled release of ~ ~b -having sizes ranging from 50 to 500 ~m, preferably fiom 90 to 300 ~m, wnich ~
capable of remaining easily in suspension in a liquid for extended times. The ,, ' comprise:
a) ~ A core of, . .~ f: - -r., with one or more optional plasticizers and excipients, granulated imto 11li. 1l 0 1PC having sizes smaUer than 500 ~m, uniform surfaces, ~ lly spherical shapes, apparent densities of about 500 to 600 g/l andvery low friabilities, which ~ obtained by wet-kneading micronised ~ ~, (and plasticrzers and excipients if present), using water or a mixture of water and other solvents. This results in ~ ~O ' with no controlled-release properties prior to coating, which have physical proper ies that ensure 1~ ' ' ' - and uniform ~' ' -of subsequent coating layers.
b) A fi}st coatii~g having essentially hydrophilic .
1~ wo96101628 2 1 ~374 P~ 112 wbich isolates the Lllil..ll- g c) A second coating baving lipophilic, ~ on top of tbe first coating.
d) A third coating having hJ~U~II;IiC ~
5Also pNvided is a vebicle system for the above contNlled-release forms, comprising either a dry mixture of additives wbich can be combined with the ~ ~ ' for long-term drug storage, or an aqueous solution with optional additivesin which the ~ contairing ~ , ~ ' can be suspended and maintained in optimum release conditions for an extended period of time. Non '- g exaunples of the 10 additives are given below.
The elements tbat comprise the 1 ' ~' r~ of the present imvention are described below without limitation:
r~ ~
1~ -O ' with a high ~ ~ content and ~ ~ physical propelties (including size, shape, density and friability) that ensure uniform coating and ' ty are formed by wet-kneading a O ' mixture comprising ~ PNcedures for mixing may be as described in U.S. Patent No. 5,296,236, or as described in co-pending U.S. Patent-Application Serial No. 08/188,193 (the "'193 20 application", now aUowed).
In a preferred ~ t, poly~ L..~, glycol, (available as Carbowax from BASF Corp., Parsippany, NJ) is added to the ,~ ~ mixture before kneading, in an amount from about 0.3 to about 1%, preferably 0.6%, relative to the weight of the mixture, to promote an optimum spherical shape and surface of 25 the, ~ ~uO.~ to be coated. PEG is highly soluble in water (i.e., at, higher than 10% W/V) and thus facilitates wettmg of ~O ~ ~ , which is relativelyinsoluble in aqueous fluids. PEG was ~u~ ...oly found to promote the formation of LUi~,ll ,, ' spherical shapes even when present at, Iower than I %. In practicing the present invention, any PEG 1..~ containing polymers of molecular 30 weight from 200 to 8000 may be used, preferably from 5000 to 7000, and most preferably PEG 6000 (CARBOWAX~ 6000).
The O containing O ~ cores may also contain optional excipients, including fillers and binders, selected without limitation from those commonly Zl 94374 ~vo 96/01628 ~ l12 ~1 used in wet mixing, such as lactose, dibasic calcium phosphate, I..ik.l~J~,lJ ~lalline cellulose, starch, talc, sugars, polyvillyl~ylll ' ' , gelatin, a copolymer Of POIYVi1IJIYY ' ' and vinyl acetate, and the like. Preferably, the I O 1P~ contain lactose as a filler (lactose content is im the range 10-50% by weight) and polyv ylL~y~ LJm as a binder S (PVP content is in the range 5-20% by weight).
Procedures for mixing may be as described in the '236 patent, or as described in the 193 A~ The n~ixing liquid used for wet-V ' for example in high-speed rnixer ~ ' can be water; or a solvent t~at is miscible with water, such as, for example, ethyl alcohol or other alcohols used in the l' 10 industry, or mixtures of water and at least one other solvent thereof.
The operating conditions for the kneading and grn~lqtinn steps are those that result in a , O ~ with optimum physical, ~ . r~ that enable the deposition of an effective coating. For example, the ' 193 application describes acceptable and preferred ranges for process parameters usmg a fast mixer and rnill, e.g., the relative 15 proportion of mixing fluid added to the dry ~ ' mixture; the rate at which the fluid is sprayed; the spray pressure; the kneading time; and the ' . ' mixer andmill speeds. The kneaded mixture is then dried to a residual humidity of 1-10%, preferably 5-8 %, and screened to select particles of the required size range. Finally, the resulting . O ' is evaluated with respect to the following properties: particle size 20 ~ ;n ~ density (aerated, packed, and apparent), Carr index ( , ' "~/), and angle of repose. Finally, as described below, the granulate is coated with films of different, ~g~
Coating the s,, containing ~ O ' in accordance with the present invention serves at least two purposes. First, the coatings prevent the release of ,, ~ in the oral cavity, thereby masking the bitter taste of . O and increasing the palatability of liquid r ~ '' comprising O ~ Second, the coatings ensure a ~ ~ " ' release profile of " delivery after it reaches the 30 gastric and intestinal milieus. Coated ~ ,O.-: s :- - containing ~, ' should comprise a pH-resistant (i.e., enteric) coating layer but it need not be the frst one applied of the at least three coatings.
~, contath~ing ~ uo.~ ate thus coated with at least three alternating WO96/01628 21 9~374 ~ 112 hydrophilic and L~,-, coating layers as descnbed below. Preferably, the last-applied coating should be Ly~L~r' "- to aid solvation amd -r ' The preferred coating technique for all of the coating below, is the fluid-bed technique in accordance with the Wuster technology tJones, D., Dr~g Dev.lndus. Pharm. 20:3175-3206, 1994).
5Substances suitable for the frrst type of coating imclude without limitation hydrophilic substances such as, for example, derivatives of cellulose (such as cellulose acetate phthalate, Lydlu~y,ulu,uy- .~1 cellulose phthalate, ethyl cellulose, carboxyl methyl cellulose acetate, and the Lke) and acrylic polymers (such as co-polymers of esters of ' yllc and acrylic acid, methyl ~' and the like). Preferably, cellulose 10 acetate phthalate or h.~dlu~yAululuyL~ rl~llulose phthalate are used. These polymers may be optionally mrb~ed with ~ such as diethyl phthalate, dibutyl sebacate, vegetable oils and the like that are well-known in controlled-release r ~ ,-Substances suitable for the second type of coating layer, which has a lipophilic nature, imclude without limitation fatty substmces such as mono-, di- and 15 tri-glycerides of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids and . ~ thereof. These coatings can be applied with the help of, ~ 1 ' solvents. Preferably, however, the waxes are applied im the melted state, with no use of solvents. Since O - has a low melting point (65~C), it is important touse conditions that allow coating without melting the ~ in the core. It has now 20 been found that the use of a coaxial nozle, wherein the spray fluid is: ~ air that is rr~ y heated to maintain the waxes constantly in the liquid state, as well ase of the 1 1 ~ of the coating chamber ~ulrlch.~lly warm, allows the waxes to coat a Lr " ~ -containing IIIL,I~ 0 ' without melting the ,.~ . rlr The same substances that make up the first coatmg layer may also be used 25 for the third coating layer. It is in any event preferred that the last-applied coating be LylLu~h;lic, as stated above.
Vehicle In practicing the present invention, the O -containing 30 ~- - " ' coated according to the above pl~ ~ s, is combined with a vehicle toform either a dry mixture that cam be suspended e~empore when needed, or a ready-to-use liquid !
For addition to the coated , O ~ comprising ~ "- ' release WO96/01628 2 i 9~jf 374 r~ ~t~12 dosage forms of , , the of the vehicle can include without limitation:
- suspending or structuring agents such as cellulose esters, ialline cellulose, algimc acid derivatives, and ~l~vh~ " ' dl,liV~liiV~
S - surfactants (preferably anionic or nonionic) such as Span 20, Span 80, Tween 20, and sodium lauryl sulfate;
- sugars such as sucrose, sorbitol, xylitol, dextrose and the like;
- buffering substances such as citric acid and sodium citrate, glycime and hydll 1 - acid, sodium phosphate, and potassium phosphate;
- ~ V~ and 1 ~ agents such as esters of p h~dlv,.~ .~.Jic acid; and - various flavormgs and sweeteners commonly used in l ' It will be understood that the specific , of the ' ' with respect to both nature and amount of added ~ ' will vary according to the 15 particular q~ nn See, e.g., Wade and Weller, eds., Hand~ook~f Mh.~ 7 E~Gipients (2d.Ed.), The r~ 1 Press, London, 1994.
In addition to the above i..l,l. ' the ready-to-use r 1 also comprises water, or mixtnres of water and pl~ acceptable water-miscible co-solvents known im the alt such as glycols, alcohols and glycerol.
20The ~ n~;lin~ of the present invention lend themselves to different forms, including, for inst~mce, (i) multi-dose granular ' ' whereim dose flexibility is obtained by measuring different amounts of granules to be re-suspended when needed; (ii) accurately ' ' single-dose r ~ " im the form of sachets;
(iu) bottles with reservoir caps for offhand 1~ and other forms known to the 25aIt. E~or pediatric use, the present invention also ~ , II,., ~ ~i" comprisimg' drops (e.g., drops containing 10% wlv O which works out to about S mg of active ingredient per drop) in which the granules contaming " are suspended.
30 Th~utic Ad The 1 - 1 r ~ " of the present invention are intended to deliver effective amounts of ~, in one or two daily: ~ An "effective amount" of ,. .c ..; is one that provides relief from coughing im a patient.
WO96/01628 2 1 943 74 P~ 112 It wiU be ' ~~ that an effective amount can be delivered at a given time by imgestion of a single dose or a plurality of doses. TypicaUy, a daily dose of ~g ~
effective in preventing and/or treating coughing is from about S to about 15 mg/kg weight of the patient. The average dose is 9 mg/kg. Thus, r ~ ~ ~ ' ' of an antitussiveS effective amount of O ~ ~ may involve once or twice daily - ' ~ ~ of about2 to about 30 ml and preferably 10 ml of a final & ~ (prepared as described in Example 8A below) containing 30 mg/ml - " ~ -The benefits of the present invention include a, ' ' '- , u._mel-t in patient . , ' , based on both a reduction in the number of daily doses and good 10 palatability. Additional benefits are anticipated in pediat~ic practice due to the ease of - ' ~ and swaUowing. r..11h~,11-~u1~;, a better therapeutic response is likely to result, since, im a preferred, ' ' t, the ~ ' permits, ~u~ 1 ;".. of dosage as a function of need simply by measuring the required suspension volumes.
The examples provided below are intended to more fully describe preferred 15 ' ' of the invention and to ~' its advantages and ~ y, without limiting its scope.
EXA~ l~ of a r~-~uistei,~e ~\T ~ " ulate A mixture made up of 79 % (w/w) ~ ~ -, 10 % (w/w) 20 pol~ I,uy11oLJu11e (PVP K30) and 10 % (w/w) 450-mesh lactose was mixed in a Diosna P25 mixer-granulator for 10 minutes. A 1% (w/w) of PEG 6000 was added as an aqueous solution to the stirred mrxture at a rate of 25 ml/min using a 0.8 mm nozzle at a pressure of 2 bars. During the wetting step the mixer speed was 175 rpm and the speed of the miU was 3000 rpm. The time required to add the solution was 20 minutes. After 25 wetting, the kneading and rounding step was performed by l~ , mixer and miU
speeds at a constant rate for 15 minutes. The ~ , O ' so obtained was dried in an artificial ., ' imcubator and then sieved through a 225-mesh/cm2 screen until a ~ , ~, ' with a granule size 1'- ' ranging from 90 to 300 ,um, a spheroidal shape, a tapped density of 0.593 g/ml, and a real density of 1.36 g/ml was obtained.
l~AM~-F 2:
Amixtnremadeupof79.4% (w/w) ~ ~ ,10% (w/w)lactose, 10%
(w/w) PVP K30 and 0.6% PEG 6000 was mixed and kneaded as in Example 1.
wo96101628 2 1 9~374 ~ 1/~ .12 ~
F~AMPLE 3: -A mixture made up of 79.4% (w/w) ,...,c,. ~.t. ' , 10% (W/W) 450-mesh lactose, 10% (w/w) PVPK30 and 0.6% (w/w) PEG 6000 was wetted with 500 ml of water, which was added at a rate of 25 ml/min over 15 minutes. PEG was added as a 5 %
S solution as in Example I above. The speed of the mixer was 175 rpm and that of the mill 3000 rpm. The O ' obtained after drying had 4% residual moisture, an untapped density of 0.548 g/ml, a tapped density of 0.669 g/ml, a Carr index of 18.08%
and an actual density of 1.38 g/ml. The above parameters are described in detail in Ellis Eorwood, Ed., (1988), M~,..~eu~lcal r,~fiu, 7~~'?n, pp. 209-214, Chichester, 10 England; and in Advances in r~ 7 Science; 2:181-220, 1967. Individualparticles within the ~g ' thus obtained exhibited a particular surface c due to the presence of PEG 6000.
EXAMPLE 4: E9rst ~51m Laver (Cellulose Acetate Phthalate) Two kg of the ~ " 1 prepared in accord,mce with Example 3 were stirred for 1 minute im a Glatt GPCG3 (Glad, GmbH, Buizen Lorrach, Germany) fluidizer into which air heated at a , of 40 to 45~C was blown at a rate of 40 m3/hour.
The granulate was sprayed at a pressure of 2 bars and a rate of 10 to 13 g/min with 400 ml of a solution havimg the following weight per-cent Cellulose acetate phthalate 4 %
Diethyl phthalate 1 %
Acetone 71 %
Isopropyl alcohol 24%
h'.~AlVlPLE 5: Second E91m Laver (Waxes) A solution having the following weight per-cent: . was prepared:
Glyceryl t~ 4.50%
White beeswax 0.40%
Cetyl alcohol 0.05%
Stearyl alcohol 0.05 %
Chloroform 90.60%
Metbanol 4 40%
~ WO 96/01628 r~ 12 1.152 g of this solution were applied to 2000 g of the ., previously coated with a first layer as described im l~xample 4. The identical operating conditions as in Example 4 for apply the second layer were used in this case.
5 F.~Al\ IPT h 6 A mixture of waxes was prepared havimg the following weight per-cent Glyceryl 90%
White beeswax 8%
Cetyl alcohol 1%
Stearyl alcohol 1%
This mixture was applied in the melted state to O ' previously coated with a first layer as described in Example 4. In this case, the waxes were first 15 melted by incubation at a ~ u~ of about 110~C. They were then sprayed in the melted state at a i ~ of about 80~C, onto 2 kg of O ~ This was ~rrr q~r~ ~ ~ usimg air pre-heated at a i . ~ of 125 ~C and: . ~Dll~ to a pressure of 3 bars using a coaxial no77:le which mixes the melted wax and the hot: ll ~ air.
The spraying step was performed with a 7" Wurster insert in a Glatt apparatus. Wax amounts equivalent to 3.8% by weight (relative to the weight of the uncoated ''1. ~ ) were sprayed at a rate of about 1.5 g/min.
~MP~li 7: TllirdF~lmLavçr The same ingredients and procedures described in Example 4 for depositing the first coating layer were used for the final coating layer ~AMPT F 8: r~ ' F ' 1~ r~ ~çinç
4 A) ~ in multi~ose bottles A " ~ , prepared as described in Example 3 and coated witn 30 three successive layers as described in Example 4, 5 and 7, was added to a final proportionofl2.5% (w/w)toamixturecontaining6.2%~ 1u~ 11inecellulose,0.8%
sodium ~IWAY '-,yk 1l ' , 0.5% sodium citrate, 0.8% citric acid, 0.2%
m~ , 0.05% ~lu~ ~ab~l., 2% tragacanth, 0.05% Span 20 surfactant. 0.2%
~WO96/01628 219~374 r~l,~ c 112 ~
ùly~ilu~l~ 0.01% glycamil, 0.25% orange-grapefruit flavor amd powdered sugar to 100%. tThe above values all represent ~ by weight.) By adding 80 g of water to 33 g of suspension mixture, a 100 ml suspension contau~ing 30 mg/ml of , O was obtained. The parabens in the foregoing ~ l serve as 5 ,u.~ aliv~ I,uuly~ilu~ule is an anti-foam agent.
B) .S A ~ in ~ ,lc ~1l packages 3.3 g of a suspension mrxture prepared as described at paragraph A were divided into individual aliquots, each comprising a single 300 mg dose of c , in paper/aluminum/polythene packages. The contents of each package may be rc s~ Pn~10 in half a glass of water C) ~5', ~. in. ~'~ ' bottles 1.25 g of a ~ .c ' , prepared as described in Example 3 and coated ~u~,c~ ,ly as described in Example 4, 5 and 7, were placed in the reservoir cap of a single-dose bottle (Bormioli Metalplast, Parma, Italy) and kept separate from the liquid 15 contained in the single-dose bottle. The ~ , of the single dose was 3,500 mg of 70% sorbitol, 15 mg of,u~.wu~le l flavors, 15 mg of citric acid, 10 mg of sodium benzoate, and purified water to 8 ml. Before use, the contents of the reservoir cap are put in contact with the liquid in the bottle by pressing the reservoir cap. Each bottle contains 300 mg of c as a smglé-dose ~ , D) p. 5 ~ -To obtain 100 ml of a ready-to-use ~n~lPn~i~m, 4 g of a ~Il;ul.c ' that had been prepared as described in Example 3 and coated with three successive layers as described in Examples 4, 5, and 6, I~",u~~ ly, were added slowly and under vacuum to a liquid vehicle having the followimg, cellulose (.ui. l~ ,Ldlline) 0.85 g sodium ~ub~Ayl..~,ll.yh.llulose 0.15 sodium lauryl sulfate 0.10 potassium sorbate 0.15 sorbitol (70% solution) 67.50 glycerin 11.80 xanthan gum 0.12 titanium dioxide 0.50 _ _ _ ~Vo96/01628 2 1 9 4 3 7 4 I_ ~ 112 ~- .ylyolyi~;loxane 0.10 ci~ic acid ' y.' 0.10 mannitol 0.40 flavor 0. 15 purified water to 100 ml This solution requires no further ~ but can be used by the patient directly as is.
EXAMP~E 9: In Vitro Te~j~ of R.qlf.Ier Release of l ~ from coated ~ ~ "' prepared as described in Examples 3, 4, 5 and 7 was tested UsiDg ~pparatus II (paddle) described in the United States rl,~ ul,or ~ Ed. XX~, operating at 75 rpm at 37~C. 900 ml of dissolution medium were used for 300 mg of 1 O Por the first hour, the dissolution medium was 0.1 N MCl and, from the second to the twelfth hours, phosphate buffer at pH 7.4.
15 The amount of active ingredient released into solution was determined ~Y~I~r11y by measuring _ ~ of the solution at 275 ~m. The p~of active ingredient released in time (hours) by a ~ ,,, ' were as follows: 21% (1 hour), 46% (2 hours), 78% (4 hours), 93% (8 hours) and 98% (12 hours).
EXAMPLE lO: ~in of 1~ ' ~akili.tv wit~ Time A) The stability of a controlled-release suspension prepared as described in Example 8, Section A was ~' ' in the following manner. The coated , ~ ' and drug vehicle component mixture was 1~ ' in water initially, 25 at 3 months, and 6 months, and the in virro release of ~.r~ r~ was tested using the procedure described in Example 9. The results are shown in Table 1:
WO 96/01628 2 1 9 4 3 7 4 I~ 12 Stability conditions % of ~ ~ - released lh 2h 4h 8h 12h Initial 22 50 77 94 95 25~C, 3 months 21 52 82 97 98 25~C, 6 months 22 52 80 95 96 35~C, 6 months 22 50 76 89 90 These data ~ that the release profile for " - was essentially unchanged even for samples that were 1~~ after storage for 6 months at 35~C.
In amother test involving an identical flqtitm the dissolution profile of the suspension was evaluated 15 days after 1lwith water. The results are shown in Table 2.
Dissolution conditions - % of m~ ~ ~ released lh 2h 4h 8h 12h Initial 22 50 77 94 95 After 15 days 21 48 79 93 95 The dissolution profile of ~, was unchanged even 15 days after 1~ with water, thus ensuring good dissolution stability throughout a typical 25 course of therapy.
B) The stability of a controlled release ready-to-use suspension prepared as described in Example 8, Section D was determined as described above by assessing the percentage of ~ ~ release initially amd after 18 months. The results are shown in Table 3.
W0961û1628 2 i ~4 3 74 I~_l/~. .l 112 Dissolution % of,, . ': released lh 2h 4h 8h 12h Initial 18 48 76 97 100 After 18 montns19 50 76 93 98 In tbis ready-to-use r 1qfinn, the dissolution profile of ,... ,O..;- s --r was unchanged after 18 months; tbis is ~li "y due to the relatively low proportion of water in the r ~ ,UI~ ' ly 30%) 10 EXAMI~J,E 11 Phvsica~ r~ r Water up to 100 ml was added to 33 g of a suspension prepared as described im Example 8. The following paTameters were then measured: 1) S. ' F, which is the ratio between the height of the sediment the height of a suspension that had been stirred allowed to st for 3 days; 2) pEI; 3) viscosity, as 15 measured with a Brookfield DVII apparatus; 4) density. The results were as follows:
F = 0.6, p~I = 4.3, Viscosity (cps) = 226, and Density (g/ml) = 1.1.
EXAMPLE 12 Bi ' ' ~ ~
A single-dose kinetic study using the ~ ' of the present invention 20 was conducted to evaluate, ,~,.; :--- b;~ v~;ld~ilily. Six healthy volunteers received a single 10 ml dose of a controlled-release bquid rl ' (equivalent to 300 mg of ) prepared as described in Example 8. Blood samples were taken at different times, and the O - plasma: (evaluated as an acid) was determined by an HPLC method. In a second t}ial, the volunteers were r ' ' ' ' c;d a dose of a uu"v, 1 2% suspension equivalent to 200 mg of ~L.Table 4 compares the main ~l - . ", ~ k .... I ;r parameters obtained fiom the two ~ Mlo ' Cmax Tmax AUC
(~g/ml) h (~g h/ml) C.R suspension 1.79 2.83 7.05 Standard suspension3.05 0.73 4.01 wo 96/01628 ~ 1 ~4 3 7 4 P~ll~ 5'~ ~ 112 C~"" = (Pea~the highest plasma ~~ - ' the drug reaches after the .~
T~"l = (Time ~" ) the time necessary to reach the C~ value;
AUCo ~ = (Area under the curve) the total area of the time-. ' profile and 5represents a measure of the b;u~v~ildlJ;liLy.
These data indicate that in the controlled-release r ~ '- of the present invention:
10(a) T,,,,~ is delayed and C",~" is reduced relative to the CUIIV~
~ . as expected for a controlled-release r~ -(b) The half-life (tl~2) amd the calculated mean residual time (MRT) are increased three-fold relative to the w..~,...iu..al , ' , and (c) The AUC and, aCWld- .,1~l, the relative b;u~v~ b;lily are lS similar to the ~,ullv~ I A
These data indicate that the suspension prepared according to the present invention exhibits the properties of a controlled release ,r ~ '- with excellent ~;U~V.~ y.
Figure I shows these results after li7~ n of a~ ~ ~ blood levels 20 for the difference between the initial ~ ~ ~ dose in the controlled-release and cu..v, ~ r, ~ The graph shows dose values (L-l) on the ordinates and time on the abscissas. The data indicate that the ~' " of ~ ~ according to the present invention permits the initial peak effect to be avoided and the number of daily dosages to be reduced, while ensuring sd~r~Lul~ therapeutic 25 blood levels of O ~ ~ over an extended time.
Figure 2 shows a simulation of blood levels of, .,~ s after two -' ' of a standard suspension or a single ~ ' ~ of the controlled-release c~ pnc~ e ~ release suspension avoids the initial peak effect (thus ~ associated side effects) observed with the standard A ' r, c;~
30 the controlled-release suspension can be used in a twice-daily ' ' ~ ' ' regimen, versus four times daily with the standard
Claims (44)
1. A controlled-release pharmaceutical dosage form suitable for the administration of moguisteine in a liquid, which comprises:
microgranules containing moguisteine as an active ingredient and optional plasticizers and excipients, said microgranules before being coated having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled release properties to said microgranules, said at least three coatings comprising alternating hydrophilic and lipophilic layers applied to said microgranules, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance over time of said release profile.
microgranules containing moguisteine as an active ingredient and optional plasticizers and excipients, said microgranules before being coated having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled release properties to said microgranules, said at least three coatings comprising alternating hydrophilic and lipophilic layers applied to said microgranules, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance over time of said release profile.
2. The dosage form of claim 1 further comprising a vehicle for the administration of said coated microgranules.
3. The dosage form of claim 1, wherein said plasticizer comprises polyethylene glycol.
4. The dosage form of claim 3, wherein said excipient comprises a compound selected from the group consisting of polyvinylpyrrolidone, lactose, dibasic calcium phosphate, microcrystalline cellulose, starch, talc, sugars, a polyvinylpyrrolidone / vinyl-acetate copolymer and gelatin.
5. The dosage form of claim 3, wherein said polyethylene glycol is present in said microgranules at a level of 0.5 to 1% by weight as compared to the total dry weight of the microgranules.
6. The dosage form of claim 1, wherein said hydrophilic coating comprises polymers selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate.
7. The dosage form of claim 6, wherein said hydrophilic coating further comprises a plasticizer selected from the group consisting of diethyl phthalate, dibutyl sebacate and vegetable oils.
8 . The dosage form of claim 7, wherein said plasticizer comprises from 10 to 30% by weight of the total weight of said hydrophilic layer.
9. The dosage form of claim 1, wherein said lipophilic coating comprises a waxy material selected from the group consisting of mono-, di- tri-glycerides of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids, and combinations thereof.
10. The dosage form of claim 9, wherein said waxy material is applied in its melted state using heated compressed air as a spray medium.
11. The dosage form of claim 2, wherein said vehicle comprises one or more agents selected from the same consisting of suspending, structuring, surfactant, sweetening, buffering, preserving, and flavoring agents and combinations of at least two of the foregoing.
12. The dosage form of claim 2, further comprising water, or mixtures of water and pharmaceutically acceptable water-miscible co-solvents selected from the group consisting of glycols, alcohols and glycerol.
13. A method for symptomatic treatment of coughing, which comprises administering antitussive effective amounts of the dosage form of claim 1.
14. A controlled release pharmaceutical dosage form suitable for the administration of moguisteine in a liquid suspension, which comprises:
microgranules containing moguisteine as an active ingredient and polyethylene glycol as a plasticizer, said microgranules before coating having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled-release properties to said microgranules, wherein a first one of said coatings comprises cellulose acetate phthalate, a second one of said coatings applied successively on said first coating comprises a mixture of glyceryl monostearate and beeswax, and a third of said coatings applied successively on said second coating comprises cellulose acetate phthalate, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and of said release profile.
microgranules containing moguisteine as an active ingredient and polyethylene glycol as a plasticizer, said microgranules before coating having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled-release properties to said microgranules, wherein a first one of said coatings comprises cellulose acetate phthalate, a second one of said coatings applied successively on said first coating comprises a mixture of glyceryl monostearate and beeswax, and a third of said coatings applied successively on said second coating comprises cellulose acetate phthalate, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and of said release profile.
15. The dosage form of claim 14, further comprising a vehicle for the administration of said coated microgranules.
16. The dosage form of claim 14, wherein said polyethylene glycol is PEG 6000.
17. A method for preparing a palatable controlled-release pharmaceutical dosage form for the administration of moguisteine in a liquid suspension, which comprises:
(a) mixing moguisteine and at least one plasticizer to form microgranules; and (b) coating the microgranules with a first, hydrophilic, coating layer comprising a polymer selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate and combinations thereof;
(c) coating the microgranules formed in (b) with a second, lipophilic, coating comprising a waxy material selected from the group of mono-,di- tri-glycerides of C6-C36 fatty acids, carnauba wax, beeswax, and candelilla wax, alcohols, fatty acids, and combinations thereof, wherein said waxy material is applied in its melted state using heated compressed air as a spray medium; and (d) coating the microgranules formed in (c) with a third, hydrophilic coating , comprising a polymer selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate and combinations thereof;
(a) mixing moguisteine and at least one plasticizer to form microgranules; and (b) coating the microgranules with a first, hydrophilic, coating layer comprising a polymer selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate and combinations thereof;
(c) coating the microgranules formed in (b) with a second, lipophilic, coating comprising a waxy material selected from the group of mono-,di- tri-glycerides of C6-C36 fatty acids, carnauba wax, beeswax, and candelilla wax, alcohols, fatty acids, and combinations thereof, wherein said waxy material is applied in its melted state using heated compressed air as a spray medium; and (d) coating the microgranules formed in (c) with a third, hydrophilic coating , comprising a polymer selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate and combinations thereof;
18. A combination for use in the symptomatic treatment of coughing, said composition comprising:
microgranules containing moguisteine as an active ingredient and optional plasticizers and excipients, said microgranules before being coated having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled release properties to said microgranules, said at least three coatings comprising alternating hydrophilic and lipophilic layers applied to said microgranules, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance over time of said release profile.
microgranules containing moguisteine as an active ingredient and optional plasticizers and excipients, said microgranules before being coated having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled release properties to said microgranules, said at least three coatings comprising alternating hydrophilic and lipophilic layers applied to said microgranules, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance over time of said release profile.
19. The composition of claim 18 further comprising a vehicle for the administration of said coated microgranules.
20. The composition of claim 18, wherein said plasticizer comprises polyethylene glycol.
21. The composition of claim 18, wherein said excipient comprises a compound selected from the group consisting of polyvinylpyrrolidone, lactose, dibasic calcium phosphate, mycrocrystalline cellulose, starch, talc, sugars, a polyvinylpyrrolidone / vinyl-acetate copolymer and gelatin.
22. The composition of claim 20, wherein said polyethylene glycol is present in said microgranules at a level of 0.5 to 1% by weight as compared to the total dry weight of the microgranules.
23. The composition of claim 18, wherein said hydrophilic coating comprises polymers selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate.
24. The composition of claim 23, wherein said hydrophilic coating further comprises a plasticizer selected from the group consisting of diethyl phthalate, dibutyl sebacate and vegetable oils.
25. The composition of claim 24, wherein said plasticizer comprises from 10 to 30% by weight of the total weight of said hydrophilic layer.
26. The composition of claim 18, wherein said lipophilic coating comprises a waxy material selected from the group consisting of mono-, di- tri-glycerides of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids, and combinations thereof.
27. The composition of claim 26, wherein said waxy material is applied in its melted state using heated compressed air as a spray medium.
28. The composition of claim 19, wherein said vehicle comprises one or more agents selected from the same consisting of suspending, structuring, surfactant sweetening, buffering, preserving, and flavoring agents and combinations of at least two of the foregoing.
29. The composition of claim 28, further comprising water, or mixtures of water and pharmaceutically acceptable water-miscible co-solvents selected from the group consisting of glycols, alcohols and glycerol.
30. A composition for use in the symptomatic treatment of coughing, said composition comprising:
microgranules containing moguisteine as an active ingredient and polyethylene glycol as a plasticizer, said before coating having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled-release properties to said a first one of said coatings comprising cellulose acetate phthalate, a second one of said coatings applied successively on said first coating comprising a mixture of glyceryl monostearate and beeswax, and a third one of said coatings applied successively on said second coating comprising cellulose acetate phthalate, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance of said release profile; and a vehicle for the administration of said coated microgranules.
microgranules containing moguisteine as an active ingredient and polyethylene glycol as a plasticizer, said before coating having a smooth surface and substantially spherical shape and no controlled-release properties, said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled-release properties to said a first one of said coatings comprising cellulose acetate phthalate, a second one of said coatings applied successively on said first coating comprising a mixture of glyceryl monostearate and beeswax, and a third one of said coatings applied successively on said second coating comprising cellulose acetate phthalate, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance of said release profile; and a vehicle for the administration of said coated microgranules.
31. The composition of claim 30 wherein said polyethylene glycol is PEG 6000.
32. The use of a controlled-release moguisteine dosage form for the symptomatic treatment of coughing, wherein said dosage form comprises:
microgranules containing moguisteine as an active ingredient and optional plasticizers and excipients, said microgranules before being coated having a smooth surface and substantially spherical shape and no controlled-release properties;
said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled release properties to said microgranules;
said at least three coatings comprising alternating hydrophilic and lipophilic layers applied directly to said microgranules, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance over time of said release profile.
microgranules containing moguisteine as an active ingredient and optional plasticizers and excipients, said microgranules before being coated having a smooth surface and substantially spherical shape and no controlled-release properties;
said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings imparting controlled release properties to said microgranules;
said at least three coatings comprising alternating hydrophilic and lipophilic layers applied directly to said microgranules, said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance over time of said release profile.
33. The use of claim 32, wherein said dosage form further comprises a vehicle for the administration of said coated microgranules.
34. The use of claim 32, wherein said plasticizer comprises polyethylene glycol.
35. The use of claim 34, wherein said excipient comprises a compound selected from the group consisting of polyvinylpyrrolidone, lactose, dibasic calcium phosphate, microcrystalline cellulose, starch, talc, sugars, a polyvinylpyrrolidone /
vinyl-acetate copolymer and gelatin.
vinyl-acetate copolymer and gelatin.
36. The use of claim 34, wherein said polyethylene glycol is present in said microgranules at a level of 0.5 to 1 % by weight as compared to the total dry weight of the microgranules.
37. The use of claim 32, wherein said hydrophylic coating comprises polymers selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate.
38. The use of claim 37, wherein said hydrophilic coating further comprises a plasticizer selected from the group consisting of diethyl phthalate, dibutyl sebacate and vegetable oils.
39. The use of claim 38, wherein said plasticizer comprises from 10 to 30% by weight of the total weight of said hydrophilic layer.
40. The use of claim 32, wherein said lipophilic coating comprises a waxy material selected from the group consisting of mono-, di- tri glycerides of C6-C36 fatty acids, carnauba wax, beeswax, candelilla wax, alcohols, fatty acids, and combinations thereof.
41. The use of claim 40, wherein said waxy material is applied in its melted state using heated compressed air as a spray medium.
42. The use of claim 33, wherein said vehicle comprises one or more agents selected from the same consisting of suspending, structuring, surfactant sweetening, buffering, preserving, and flavoring agents and combinations of at least two of the foregoing.
43. The use of claim 42, further comprising water, or mixtures of water and pharmaceutically acceptable water-miscible co-solvents selected from the group consisting of glycols, alcohols and glycerol.
44. The use of a controlled-release moguisteine dosage form for the symptomatic treatment of coughing, wherein said dosage form comprises:
microgranules containing moguisteine as an active ingredient and polyethylene glycol as a plasticizer, said microgranules before coating having a smooth surface and substantially spherical shape and no controlled-release properties;
said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings importing controlled-release properties to said microgranules;
a first one of said coatings comprising cellulose acetate phthalate, a second one of said coatings applied successively on a said first coating comprising a mixture of glyceryl monostearate and beeswax, and the third one of said coatings applied successively on said second coating comprising cellulose acetate phthalate;
said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance of said release profile; and a vehicle for the administration of said coated microgranules.
microgranules containing moguisteine as an active ingredient and polyethylene glycol as a plasticizer, said microgranules before coating having a smooth surface and substantially spherical shape and no controlled-release properties;
said microgranules comprising a plurality of at least three coatings thereon, at least one of said coatings importing controlled-release properties to said microgranules;
a first one of said coatings comprising cellulose acetate phthalate, a second one of said coatings applied successively on a said first coating comprising a mixture of glyceryl monostearate and beeswax, and the third one of said coatings applied successively on said second coating comprising cellulose acetate phthalate;
said coatings preventing tastable dissolution of said moguisteine upon ingestion and ensuring a predetermined sustained release profile of moguisteine and maintenance of said release profile; and a vehicle for the administration of said coated microgranules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI94A001410 | 1994-07-07 | ||
ITMI941410A IT1270594B (en) | 1994-07-07 | 1994-07-07 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2194374A1 true CA2194374A1 (en) | 1996-01-25 |
Family
ID=11369231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002194374A Abandoned CA2194374A1 (en) | 1994-07-07 | 1995-05-29 | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension |
Country Status (12)
Country | Link |
---|---|
US (1) | US5674533A (en) |
EP (1) | EP0769948A1 (en) |
JP (1) | JPH10502629A (en) |
KR (1) | KR970704437A (en) |
AU (1) | AU2417695A (en) |
BR (1) | BR9510302A (en) |
CA (1) | CA2194374A1 (en) |
CZ (1) | CZ287967B6 (en) |
HU (1) | HUT76832A (en) |
IT (1) | IT1270594B (en) |
MX (1) | MX9700223A (en) |
WO (1) | WO1996001628A1 (en) |
Families Citing this family (882)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6858589B2 (en) | 1996-01-25 | 2005-02-22 | Pharmacy And Therapeutic Advisory Consultancy Pty Ltd | Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria |
US5900258A (en) * | 1996-02-01 | 1999-05-04 | Zeolitics Inc. | Anti-bacterial compositions |
NZ334148A (en) * | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
DE19706978A1 (en) * | 1997-02-21 | 1998-08-27 | Ulrich Dr Posanski | Combination preparation for oral antibiotics |
TR200103058T2 (en) | 1998-06-15 | 2002-06-21 | Sepracor Inc. | The use of optically pure (+) - norcisapride for treating apnea, bulimia and other disorders. |
TR200103759T2 (en) | 1998-06-15 | 2002-06-21 | Sepracor Inc. | The use of optically pure (-) norcisapride to treat apnea, bulimia and other disorders |
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
JP2000128774A (en) | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | Production of globular, fine grain including medicine |
US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
JP2002538102A (en) | 1999-03-01 | 2002-11-12 | セプラコア インコーポレーテッド | Method of treating apnea and apnea disorder using optically pure R (+) ondansetron |
US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6428818B1 (en) | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
US6410052B1 (en) | 1999-03-30 | 2002-06-25 | Purdue Research Foundation | Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
DE60039132D1 (en) * | 1999-04-06 | 2008-07-17 | Sepracor Inc | O-desmethylvenlafaxine succinate |
BR0009557A (en) | 1999-04-06 | 2002-05-28 | Ethypharm Lab Prod Ethiques | Pharmaceutical suspension for ibuprofen drinking |
US6951873B1 (en) | 1999-04-27 | 2005-10-04 | Pfizer Inc. | Methods for treating age-related behavioral disorders in companion animals |
ES2256032T3 (en) * | 1999-09-03 | 2006-07-16 | Apbi Holdings, Llc | USE OF DAPOXETINE, A SELECTIVE INHIBITOR OF RECOVERY OF SEROTONINE, FOR THE TREATMENT OF A SEXUAL DYSFUNCTION. |
RU2002113076A (en) | 1999-11-18 | 2004-03-10 | Корвас Интернэшнл, Инк. (Us) | Nucleic acids encoding endotheliases, endotheliases and their use |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
KR100574213B1 (en) * | 2000-01-27 | 2006-04-27 | 다나베 세이야꾸 가부시키가이샤 | Sustained-release preparation and process for producing the same |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
CN1420776A (en) * | 2000-03-31 | 2003-05-28 | 塞尔基因公司 | Inhibition of cyclooxygenase-2 activity |
US7259152B2 (en) | 2000-06-07 | 2007-08-21 | Alfa Wasserman, Inc. | Methods and compositions using sulodexide for the treatment of diabetic nephropathy |
US20070208087A1 (en) * | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
ES2290091T3 (en) * | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | SYNTHESIS OF ENANTIOMERS OF 4-AMINO-TALIDOMIDE. |
US20030167524A1 (en) * | 2000-12-19 | 2003-09-04 | Rooijen Gijs Van | Methods for the production of multimeric protein complexes, and related compositions |
PT1360169E (en) * | 2001-02-12 | 2007-10-29 | Wyeth Corp | Succinate salt of o-desmethyl-venlafaxine |
FR2821747B1 (en) * | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | SUSPENSION OF TELITHROMYCIN WITH A MASK TASTE |
FR2821745B1 (en) * | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | GRANULES AND GRANULES COATED WITH MASK TASTE |
WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
US7172892B2 (en) | 2001-03-22 | 2007-02-06 | Dendreon Corporation | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon |
WO2002077267A2 (en) | 2001-03-27 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
CA2447050A1 (en) | 2001-05-14 | 2002-11-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
US20040247696A1 (en) * | 2001-07-05 | 2004-12-09 | Antelman Marvin S. | Methods of using electron active compounds for managing conditions afflicting mammals |
US20030087963A1 (en) | 2001-09-13 | 2003-05-08 | Senanayake Chris H. | Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites |
AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
EP1542719A4 (en) | 2001-12-05 | 2006-06-21 | Baylor College Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
US20040009953A1 (en) * | 2002-01-10 | 2004-01-15 | Comper Wayne D. | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
US20030181416A1 (en) * | 2002-01-10 | 2003-09-25 | Comper Wayne D. | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
ES2345044T3 (en) | 2002-02-01 | 2010-09-14 | Euro-Celtique S.A. | 2-PIPERAZIN-PIRIDINES USEFUL TO TREAT THE PAIN. |
US7078526B2 (en) * | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US7446107B2 (en) * | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
AU2003213719A1 (en) | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
WO2003084517A2 (en) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Oral suspension of amoxicillin capsules |
PT1492511E (en) * | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
FR2843881B1 (en) * | 2002-09-02 | 2006-06-02 | Flamel Tech Sa | ORAL PHARMACEUTICAL FORMULATION AS AQUEOUS SUSPENSION OF MICROCAPSULES FOR MODIFIED RELEASE OF ACTIVE (S) PRINCIPLE (S) |
US7205413B2 (en) * | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
EP1556033A4 (en) * | 2002-05-17 | 2006-05-31 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
EP2915533B1 (en) | 2002-05-17 | 2017-09-13 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
PT1511710E (en) | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US8829198B2 (en) * | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
US6995168B2 (en) * | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
AU2003243699B2 (en) * | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
CA2493458A1 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
EP1527434A1 (en) * | 2002-07-29 | 2005-05-04 | Koninklijke Philips Electronics N.V. | Driving a plasma display panel |
WO2004029059A1 (en) | 2002-09-25 | 2004-04-08 | Euro-Celtique S.A. | N-substituted hydromorphones and the use thereof |
AU2003276988B2 (en) * | 2002-09-27 | 2009-11-05 | Bioenvision, Inc. | Methods and compositions for the treatment of autoimmune disorders using clofarabine |
AU2003276987B2 (en) * | 2002-09-27 | 2009-07-30 | Bioenvision, Inc. | Methods and compositions for the treatment of lupus using clofarabine |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
AU2003228509B2 (en) * | 2002-10-15 | 2008-06-26 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
BR0316057A (en) | 2002-11-06 | 2005-09-20 | Celgene Corp | Methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis and of reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy or immunotherapy in a patient suffering from a specific cancer, pharmaceutical composition and kit |
AU2003226361B2 (en) * | 2002-11-06 | 2009-01-22 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
MXPA05005161A (en) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Methods of usig and compositions comprising (-)-3- (3, 4- dimethoxy -phenyl)-3 -(1-oxo-1, 3-dihydro- isoindol- 2-yl)- propionamide. |
US7202259B2 (en) * | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
CN1738613A (en) * | 2002-11-18 | 2006-02-22 | 细胞基因公司 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US6864251B2 (en) | 2002-12-03 | 2005-03-08 | Vela Pharmaceuticals, Inc. | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines |
AU2003297199A1 (en) * | 2002-12-16 | 2004-07-22 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
EP2339328A3 (en) | 2002-12-30 | 2011-07-13 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of celecoxib |
AU2003272270A1 (en) | 2003-02-28 | 2004-09-28 | The Regents Of The University Of Michigan | Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20040186180A1 (en) | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
HUE059464T2 (en) | 2003-04-11 | 2022-11-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
WO2004091278A2 (en) * | 2003-04-11 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Gabapentin compositions |
WO2005016966A2 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
WO2005000786A1 (en) * | 2003-05-23 | 2005-01-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
US20100331380A1 (en) * | 2009-06-29 | 2010-12-30 | Esposito Luke A | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies |
US8916598B2 (en) | 2003-05-30 | 2014-12-23 | Proteotech Inc | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies |
US7438903B2 (en) * | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
CN1319955C (en) * | 2003-06-10 | 2007-06-06 | 浙江海正药业股份有限公司 | Moguisteine crystallographic form |
AR044688A1 (en) * | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN |
ES2322707T3 (en) * | 2003-07-03 | 2009-06-25 | Euro-Celtique S.A. | USED ALKIN 2-PYRIDINE DERIVATIVES TO TREAT PAIN. |
WO2005004882A1 (en) * | 2003-07-09 | 2005-01-20 | Monash University | Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof |
KR20060058092A (en) | 2003-07-23 | 2006-05-29 | 신타 파마슈티칼스 코프. | Compounds for inflammation and immune-related uses |
CN101914088A (en) | 2003-07-24 | 2010-12-15 | 尤罗塞尔蒂克股份有限公司 | Piperidine compounds and pharmaceutical compositions containing them |
EP2080757A1 (en) * | 2003-07-24 | 2009-07-22 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
PL1867644T3 (en) | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
CN1832935A (en) | 2003-08-01 | 2006-09-13 | 欧洲凯尔特公司 | Therapeutic agents useful for treating pain |
WO2005020954A2 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
DK1664041T3 (en) * | 2003-09-22 | 2008-10-27 | Euro Celtique Sa | Phenylcarboxamide compounds suitable for the treatment of pain |
ATE412646T1 (en) * | 2003-09-22 | 2008-11-15 | Euro Celtique Sa | THERAPEUTIC AGENTS SUITABLE FOR THE TREATMENT OF PAIN |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20050113410A1 (en) * | 2003-11-03 | 2005-05-26 | Mark Tawa | Pharmaceutical salts of zafirlukast |
CN1901911A (en) * | 2003-11-06 | 2007-01-24 | 细胞基因公司 | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
US7470435B2 (en) * | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
NZ547689A (en) | 2003-11-19 | 2009-05-31 | Signal Pharm Llc | Indazole compounds and methods of use thereof as protein kinase inhibitors |
KR100589357B1 (en) * | 2003-11-27 | 2006-06-14 | 삼성에스디아이 주식회사 | Plasma display panel which is suitable for spreading phosphors |
AU2004312398B8 (en) * | 2003-12-30 | 2008-10-09 | Euro-Celtique S.A. | Piperazines useful for treating pain |
EP2292213A1 (en) | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
EP1722758A1 (en) * | 2004-02-11 | 2006-11-22 | Athpharma Limited | Chronotherapeutic compositions and methods of their use |
CA2555811A1 (en) | 2004-02-18 | 2005-08-25 | Gpc Biotech Ag | Methods for treating resistant or refractory tumors |
JP2007530544A (en) | 2004-03-22 | 2007-11-01 | セルジーン・コーポレーション | Methods of using immunomodulatory compounds for treating and managing skin diseases or disorders and compositions containing the same |
US20060004037A1 (en) * | 2004-03-25 | 2006-01-05 | Transform Pharmaceuticals, Inc. | Novel tricyclic compounds and related methods of treatment |
CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
EP1744749A4 (en) * | 2004-04-14 | 2009-04-22 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
WO2005102317A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
KR20050105411A (en) * | 2004-05-01 | 2005-11-04 | 삼성에스디아이 주식회사 | Plasma display panel |
US7803366B2 (en) * | 2004-05-07 | 2010-09-28 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
EP1745073A2 (en) * | 2004-05-14 | 2007-01-24 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
WO2005117585A1 (en) | 2004-05-28 | 2005-12-15 | Transform Pharmaceuticals, Inc. | Mixed co-crystals and pharmaceutical compositions comprising the same |
WO2005120584A2 (en) * | 2004-06-03 | 2005-12-22 | The Trustees Of Columbia University In The City Of New York | Radiolabeled arylsulfonyl compounds and uses thereof |
JP5017103B2 (en) * | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | Pharmaceutical co-crystal composition and related methods of use |
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
AU2005271407A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
CA2576196A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
NZ588431A (en) | 2004-09-17 | 2012-02-24 | Whitehead Biomedical Inst | Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity |
CN101083985A (en) | 2004-09-21 | 2007-12-05 | 幸讬制药公司 | Compounds for inflammation and immune-related uses |
EP1811992A2 (en) * | 2004-10-28 | 2007-08-01 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
WO2006053184A2 (en) * | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing a vascular disease |
CN101072759B (en) | 2004-11-18 | 2013-06-19 | Synta医药公司 | Triazole compounds that modulate HSP90 activity |
ES2401285T3 (en) | 2004-12-16 | 2013-04-18 | The Regents Of The University Of California | Drugs with lung as target |
CN102504001B (en) | 2004-12-17 | 2015-02-25 | 安那迪斯药品股份有限公司 | 3, 5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof |
ATE432921T1 (en) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | SQUARE ACID DERIVATIVES WITH ANTIPROLIFERATIVE EFFECT |
US20060160783A1 (en) * | 2004-12-30 | 2006-07-20 | Transform Pharmaceuticals, Inc. | Novel omeprazole forms and related methods |
TWI441819B (en) * | 2005-01-07 | 2014-06-21 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
TWI422376B (en) | 2005-01-25 | 2014-01-11 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
US8318210B2 (en) * | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
US20060216355A1 (en) * | 2005-03-28 | 2006-09-28 | Donald Spector | Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
US8222257B2 (en) | 2005-04-01 | 2012-07-17 | The Regents Of The University Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
JP2008539731A (en) | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | Compositions and methods for diagnosis and treatment of cancer |
WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
US20070041944A1 (en) * | 2005-05-05 | 2007-02-22 | The Trustees Of Columbia University In The City Of New York | Treating tumors by ENH dislocation of ID proteins |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
WO2007002109A2 (en) * | 2005-06-20 | 2007-01-04 | The Regents Of The University Of California | Multidentate pyrone-derived chelators for medicinal imaging and chelation |
US20070054868A1 (en) * | 2005-06-20 | 2007-03-08 | The Trustees Of Columbia University In The City Of New York | Synergistic polyphenol compounds, compositions thereof, and uses thereof |
MX2008000249A (en) * | 2005-07-06 | 2008-03-18 | Sepracor Inc | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders. |
AU2006272922A1 (en) | 2005-07-22 | 2007-02-01 | Amgen Inc. | Aniline sulfonamide derivatives and their uses |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
CA2899923A1 (en) | 2005-08-31 | 2007-03-08 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
WO2008051197A2 (en) * | 2005-09-20 | 2008-05-02 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
WO2007056155A1 (en) | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
EP1954714A2 (en) * | 2005-11-10 | 2008-08-13 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
EP2289497A1 (en) | 2005-11-10 | 2011-03-02 | Circ Pharma Research and Development Limited | Once-daily administration of central nervous system drugs |
NZ568430A (en) * | 2005-11-21 | 2011-02-25 | Purdue Pharma Lp | 4-oxadiazolyl-piperidine compounds and use thereof |
WO2007076160A2 (en) * | 2005-12-28 | 2007-07-05 | Acidophil Llc | C-10 carbamates of taxanes |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
EP1981525B1 (en) * | 2005-12-30 | 2015-01-21 | Zensun (Shanghai) Science and Technology Limited | Extended release of neuregulin for improved cardiac function |
US8455658B2 (en) * | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
US7816535B2 (en) | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
EP1998612A4 (en) | 2006-01-25 | 2010-11-24 | Synta Pharmaceuticals Corp | Substituted biaryl compounds for inflammation and immune-related uses |
AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
US7518017B2 (en) | 2006-02-17 | 2009-04-14 | Idexx Laboratories | Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds |
MX2008011844A (en) * | 2006-03-13 | 2008-10-02 | Encysive Pharmaceuticals Inc | Formulations of sitaxsentan sodium. |
PL2383271T3 (en) * | 2006-03-13 | 2013-12-31 | Kyorin Seiyaku Kk | Aminoquinolones as GSK-3 Inhibitors |
EP1996162A2 (en) * | 2006-03-13 | 2008-12-03 | Encysive Pharmaceuticals, Inc | Methods and compositions for treatment of diastolic heart failure |
BRPI0709699A2 (en) * | 2006-03-29 | 2011-07-26 | Foldrx Pharmaceuticals Inc | inhibition of alpha synuclein toxicity |
AU2007259143A1 (en) * | 2006-06-08 | 2007-12-21 | Amgen Inc. | Benzamide derivatives and uses related thereto |
TW200808695A (en) * | 2006-06-08 | 2008-02-16 | Amgen Inc | Benzamide derivatives and uses related thereto |
NZ574093A (en) * | 2006-06-12 | 2011-03-31 | Symphogen As | Pan-cell surface receptor- specific therapeutics |
US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
MX2008016519A (en) | 2006-06-22 | 2009-01-30 | Anadys Pharmaceuticals Inc | Pyrro[1,2-b]pyridazinone compounds. |
TWI418561B (en) | 2006-06-22 | 2013-12-11 | Anadys Pharmaceuticals Inc | Prodrugs of 5-amino-3-(3'-deoxy-β-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
TWI369402B (en) | 2006-07-05 | 2012-08-01 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
WO2008008373A2 (en) | 2006-07-11 | 2008-01-17 | Arubor Corp | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
US7528115B2 (en) | 2006-07-18 | 2009-05-05 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines |
CL2007002218A1 (en) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA. |
US20080045603A1 (en) * | 2006-08-04 | 2008-02-21 | John Devane | Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
AU2007297597B2 (en) | 2006-09-21 | 2013-02-21 | Kyorin Pharmaceuticals Co., Ltd. | Serine hydrolase inhibitors |
US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
PL2124556T3 (en) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Pharmaceutical compositions |
EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
US20110046164A1 (en) | 2006-10-19 | 2011-02-24 | Genzyme Corporation | Purine Derivatives for Treatment of Cystic Diseases |
JP2010507585A (en) | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | Substituted indole |
WO2008057604A2 (en) * | 2006-11-08 | 2008-05-15 | The Regents Of The University Of California | Small molecule therapeutics, syntheses of analogues and derivatives and methods of use |
US20080207641A1 (en) | 2006-11-13 | 2008-08-28 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
WO2008076270A2 (en) | 2006-12-13 | 2008-06-26 | Temple University-Of The Commonwealth System Of Higher Education | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof |
WO2008079371A1 (en) * | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
AU2007343726A1 (en) * | 2006-12-26 | 2008-07-24 | Amgen Inc. | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
ES2353448T3 (en) | 2007-01-16 | 2011-03-02 | Purdue Pharma L.P. | HETEROCYCLIC-SUBSTITUTED PIPERIDINS AS LIGANDOS OF ORL-1. |
FR2911506B1 (en) * | 2007-01-18 | 2009-07-03 | Ceva Sante Animale Sa | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION IN THE FORM OF STABILIZED AQUEOUS SUSPENSIONS |
US8999395B2 (en) | 2007-02-09 | 2015-04-07 | Ceva Sante Animale | Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions |
JP5322951B2 (en) | 2007-02-09 | 2013-10-23 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Novel antagonist of glucagon receptor |
AR065431A1 (en) | 2007-02-21 | 2009-06-10 | Sepracor Inc | SOLID FORMS THAT INCLUDE (-) -O-DEMETILVENLAFAXIN AND USES OF THE SAME. |
PL2144604T3 (en) * | 2007-02-28 | 2012-02-29 | Conatus Pharmaceuticals Inc | Methods for the treatment of chronic viral hepatitis C using RO 113-0830 |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
EP3103790B1 (en) | 2007-03-15 | 2018-05-09 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamine with serotoninergic and/or norepinephrinergic activity |
CA2683415C (en) | 2007-04-04 | 2020-12-08 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
EP2586428B1 (en) | 2007-04-26 | 2023-11-08 | Sublimity Therapeutics Limited | Manufacture of multiple minicapsules |
JP5462784B2 (en) | 2007-04-27 | 2014-04-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | TRPV1 antagonists and uses thereof |
AU2008246202B2 (en) | 2007-04-27 | 2011-12-01 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
US7892776B2 (en) | 2007-05-04 | 2011-02-22 | The Regents Of The University Of California | Screening assay to identify modulators of protein kinase A |
EP2019101A1 (en) * | 2007-07-26 | 2009-01-28 | GPC Biotech AG | Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor |
KR101581289B1 (en) | 2007-05-31 | 2015-12-31 | 세프라코 아이엔시. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
AU2008287542C1 (en) | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
US8415294B2 (en) * | 2007-06-05 | 2013-04-09 | Arizona Board Of Regents | Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth |
AU2008275752A1 (en) * | 2007-07-06 | 2009-01-15 | Nuon Therapeutics, Inc. | Treatment of neuropathic pain |
CN101801188A (en) * | 2007-07-12 | 2010-08-11 | 特拉加拉医药品公司 | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
WO2009012263A2 (en) * | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
US8349841B2 (en) | 2007-08-01 | 2013-01-08 | Synta Pharmaceuticals Corp. | Vinyl-aryl derivatives for inflammation and immune-related uses |
CA2695143A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Heterocycle-aryl compounds for inflammation and immune-related uses |
WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
JP5572549B2 (en) | 2007-08-13 | 2014-08-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Novel activator of glucokinase |
US20090062242A1 (en) * | 2007-08-28 | 2009-03-05 | Agi Therapeutics Plc | Methods and compositions for treating gastrointestinal conditions |
TWI448289B (en) | 2007-08-31 | 2014-08-11 | Purdue Pharma Lp | Substituted-quinoxaline-type piperidine compounds and the uses thereof |
AU2008299903B2 (en) * | 2007-09-11 | 2013-08-29 | Kyorin Pharmaceutical Co., Ltd | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors |
CN101855229A (en) | 2007-09-12 | 2010-10-06 | 埃迪威克斯生物科学公司 | Spirocyclic aminoquinolones as GSK-3 inhibitors |
CN104211684A (en) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same |
US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
US20100278801A1 (en) * | 2007-10-16 | 2010-11-04 | Shepard H Michael | Compositions comprising optimized her1 and her3 multimers and methods of use thereof |
WO2009051772A1 (en) * | 2007-10-17 | 2009-04-23 | Duke University | Geranylgeranyl transferase inhibitors and methods of making and using the same |
WO2009052454A2 (en) | 2007-10-19 | 2009-04-23 | University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
US8293513B2 (en) | 2007-12-14 | 2012-10-23 | Georgetown University | Histone deacetylase inhibitors |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
WO2009111611A2 (en) * | 2008-03-05 | 2009-09-11 | Proteotech Inc. | Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes |
TWI395593B (en) | 2008-03-06 | 2013-05-11 | Halozyme Inc | In vivo temporal control of activatable matrix-degrading enzymes |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
MX2010010172A (en) | 2008-03-17 | 2010-11-25 | Ambit Biosciences Corp | Quinazoline derivatives as raf kinase modulators and methods of use thereof. |
US9249147B2 (en) | 2008-03-19 | 2016-02-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
KR20140142323A (en) | 2008-03-27 | 2014-12-11 | 셀진 코포레이션 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
EP2687213B1 (en) | 2008-03-27 | 2019-01-23 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
SG187427A1 (en) | 2008-04-14 | 2013-02-28 | Halozyme Inc | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
NZ589469A (en) * | 2008-05-20 | 2012-08-31 | Cerenis Therapeutics Holding S A | Niacin and NSAID combination for reducing niacin-induced flushing |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
AU2009277172B2 (en) | 2008-07-02 | 2014-05-29 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
UA99540C2 (en) | 2008-07-21 | 2012-08-27 | Пердью Фарма Л.П. | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
ME01665B (en) | 2008-07-30 | 2014-09-20 | Purdue Pharma Lp | Buprenorphine analogs |
KR101599089B1 (en) | 2008-08-13 | 2016-03-02 | 메타베이시스 테라퓨틱스, 인크. | Glucagon antagonists |
EP2348863A4 (en) | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
JP2012502915A (en) | 2008-09-15 | 2012-02-02 | バイオビスタ インコーポレイテッド | Compositions and methods for treating epilepsy |
WO2010039237A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
WO2010042834A1 (en) | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
WO2010042796A1 (en) * | 2008-10-10 | 2010-04-15 | Purdue Research Foundation | Compounds for treatment of alzheimer's disease |
US8546388B2 (en) * | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
MX2011004470A (en) | 2008-10-29 | 2011-05-31 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer. |
EP2376083A4 (en) * | 2008-11-20 | 2012-06-20 | Purdue Research Foundation | Quinazoline inhibitors of bace 1 and methods of using |
US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
KR101546563B1 (en) | 2008-12-09 | 2015-08-28 | 할로자임, 아이엔씨 | Extended soluble ph20 polypeptides and uses thereof |
CN102317261B (en) | 2008-12-16 | 2015-11-25 | 桑诺维恩药品公司 | Triple reuptake inhibitor and application method thereof |
AU2009330192A1 (en) | 2008-12-22 | 2011-07-14 | Sloan-Kettering Institute For Cancer Research | Methods for treating or preventing cancer and neurodegenerative diseases |
CA2747811A1 (en) | 2008-12-22 | 2010-07-01 | Sloan-Kettering Institute For Cancer Research | Coumarin-based compounds |
US8536114B2 (en) | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
AU2010203709B2 (en) | 2009-01-06 | 2014-05-22 | Galenagen, Llc | Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces |
CA2747703C (en) | 2009-01-06 | 2021-06-15 | Curemark Llc | Compositions and methods for the treatment or the prevention of infections by e. coli |
WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
CN102340992B (en) | 2009-02-09 | 2014-11-05 | 桑诺维恩药品公司 | Pyrrolidine triple reuptake inhibitors |
CA2750123A1 (en) | 2009-02-10 | 2010-08-19 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
SG173639A1 (en) | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
KR20170053733A (en) * | 2009-02-24 | 2017-05-16 | 리터 파마슈티컬즈 인코오포레이티드 | Prebiotic formulations and methods of use |
WO2010099508A1 (en) | 2009-02-26 | 2010-09-02 | Theraquest Biosciences, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
MY159327A (en) * | 2009-02-27 | 2016-12-25 | Ambit Biosciences Corp | Jak kinase modulating quinazoline derivatives and methods of use thereof |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
US20110229451A2 (en) * | 2009-03-06 | 2011-09-22 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloproteases and uses thereof |
BRPI1008974A2 (en) * | 2009-03-11 | 2017-06-06 | Kyorin Seiyaku Kk | compound, pharmaceutical composition, and method for treating, preventing or ameliorating a gsk-3 mediated disease |
JP2012520314A (en) | 2009-03-11 | 2012-09-06 | アムビト ビオスシエンセス コルポラチオン | Combination of indazolylaminopyrrolotriazine and taxane for cancer treatment |
NZ595372A (en) | 2009-03-27 | 2013-11-29 | Vetdc Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
CA2758976C (en) | 2009-04-20 | 2015-02-03 | Alain Baron | Chemosensory receptor ligand-based therapies |
DK2421829T3 (en) | 2009-04-22 | 2016-01-04 | Axikin Pharmaceuticals Inc | 2,5-disubstituted aryl sulfonamide CCR3 antagonists |
PE20150925A1 (en) | 2009-04-22 | 2015-06-14 | Axikin Pharmaceuticals Inc | CCR3 ANTAGONISTS OF ARYLSULFONAMIDE 2,5-DISUSTITUID |
PE20150759A1 (en) | 2009-04-22 | 2015-05-15 | Axikin Pharmaceuticals Inc | CCR3 ARYLSULFONAMIDE ANTAGONISTS |
US9968574B2 (en) * | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
US20100292281A1 (en) * | 2009-05-15 | 2010-11-18 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
US9278070B2 (en) | 2009-05-18 | 2016-03-08 | Sigmoid Pharma Limited | Composition comprising oil drops |
JP5645816B2 (en) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | Pharmaceutical composition comprising core factor related to proliferation and differentiation of central nerve cell |
CA2764808A1 (en) | 2009-06-10 | 2010-12-16 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
WO2011003870A2 (en) | 2009-07-06 | 2011-01-13 | Creabilis S.A. | Mini-pegylated corticosteroids, compositions including same, and methods of making and using same |
EP2451802A1 (en) | 2009-07-07 | 2012-05-16 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
JP5905387B2 (en) | 2009-07-08 | 2016-04-20 | ホープ メディカル エンタープライゼズ,インコーポレイテッド ディービーエー ホープ ファーマシュティカルズHope Medical Enterprises,Inc.Dba Hope Pharmaceuticals | Pharmaceutical composition containing sodium thiosulfate |
EP2467144A1 (en) | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
WO2011014775A1 (en) | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
GB2485327A (en) | 2009-08-12 | 2012-05-09 | Sigmoid Pharma Ltd | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
MX2012001974A (en) | 2009-08-19 | 2012-04-11 | Ambit Biosciences Corp | Biaryl compounds and methods of use thereof. |
NZ599215A (en) | 2009-09-04 | 2014-11-28 | United Paragon Associates Inc | Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity |
US20120172350A1 (en) | 2009-09-11 | 2012-07-05 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
US20110136751A1 (en) | 2009-10-06 | 2011-06-09 | Green Molecular | Use of Polyphenols in the Treatment of Cancer |
MX2012004577A (en) | 2009-10-19 | 2012-06-13 | Synta Pharmaceuticals Corp | Combination cancer therapy with hsp90 inhibitory compounds. |
US8470817B2 (en) * | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
EP2325185A1 (en) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Plk inhibitor |
WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
CN102781443A (en) | 2009-11-19 | 2012-11-14 | 细胞基因公司 | Apremilast For The Treatment Of Sarcoidosis |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
LT2501234T (en) * | 2009-11-20 | 2017-12-11 | Tonix Pharma Holdings Limited | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
WO2011064769A1 (en) | 2009-11-24 | 2011-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and pharmaceutical compositions for the treatment of hot flashes |
WO2011069002A1 (en) | 2009-12-02 | 2011-06-09 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
SG181466A1 (en) | 2009-12-04 | 2012-07-30 | Sunovion Pharmaceuticals Inc | Formulations, salts and polymorphs of transnorsertraline and uses thereof |
CN102762575B (en) | 2009-12-04 | 2015-04-15 | 桑诺维恩药品公司 | Multicyclic compounds and methods of use thereof |
CN102869367A (en) | 2009-12-09 | 2013-01-09 | 西尼克斯公司 | Novel cyclic peptides |
SG181797A1 (en) | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
WO2011079091A1 (en) | 2009-12-22 | 2011-06-30 | Celgene Corporation | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
WO2011079313A1 (en) * | 2009-12-23 | 2011-06-30 | Map Pharmaceuticals, Inc. | Novel ergoline analogs |
US20120010131A1 (en) | 2009-12-30 | 2012-01-12 | Scynexis, Inc. | Novel cyclosporin analogues |
ES2699692T3 (en) | 2010-01-04 | 2019-02-12 | Mapi Pharma Ltd | Deposit system comprising glatiramer acetate |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
EP2851070A1 (en) | 2010-01-05 | 2015-03-25 | Celgene Corporation | A combination of lenalidomide and artesunate/artemisone for treating cancer |
WO2011089166A1 (en) | 2010-01-19 | 2011-07-28 | Virologik Gmbh | Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
WO2011097525A1 (en) | 2010-02-05 | 2011-08-11 | Tragara Pharmaceuticals, Inc. | Solid state forms of macrocyclic kinase inhibitors |
MX337169B (en) | 2010-02-11 | 2016-02-16 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same. |
EP2542542B1 (en) | 2010-03-02 | 2015-04-22 | Axikin Pharmaceuticals, Inc. | Isotopically enriched arylsulfonamide ccr3 antagonists |
WO2011112689A2 (en) | 2010-03-11 | 2011-09-15 | Ambit Biosciences Corp. | Saltz of an indazolylpyrrolotriazine |
MX2012010367A (en) | 2010-03-12 | 2012-11-23 | Celgene Corp | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor. |
JP5818873B2 (en) | 2010-03-17 | 2015-11-18 | アクシキン ファーマシューティカルズ インコーポレーテッド | Arylsulfonamide CCR3 antagonist |
EP2547203A4 (en) | 2010-03-19 | 2013-12-25 | Purdue Research Foundation | Ccr5 modulators for treating hiv |
MX341050B (en) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Methods for treating respiratory viral infection. |
EP2556082B1 (en) | 2010-04-08 | 2017-02-22 | Emory University | Substituted androst-4-ene diones |
US20130156755A1 (en) | 2010-04-19 | 2013-06-20 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
WO2011140360A1 (en) | 2010-05-05 | 2011-11-10 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
AU2011255438A1 (en) | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
US20120064175A1 (en) | 2010-05-20 | 2012-03-15 | Synta Pharmaceuticals Corp. | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients |
WO2011149824A1 (en) | 2010-05-24 | 2011-12-01 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
AU2011258217B2 (en) | 2010-05-26 | 2016-12-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
WO2011150201A2 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl amide compounds and methods of use thereof |
CN102918031A (en) | 2010-05-28 | 2013-02-06 | 通用电气健康护理有限公司 | Radiolabeled compounds and methods thereof |
MX2012013879A (en) | 2010-06-01 | 2013-04-03 | Biotheryx Inc | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases. |
CN103153309A (en) | 2010-06-01 | 2013-06-12 | 拜欧赛里克斯公司 | Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone |
AU2011265047B2 (en) | 2010-06-07 | 2014-10-23 | Novomedix, Llc | Furanyl compounds and the use thereof |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US20140200270A1 (en) | 2013-01-11 | 2014-07-17 | Summa Health System | Vitamins c and k for treating polycystic diseases |
CA2805745C (en) | 2010-07-19 | 2019-01-15 | Summa Health System | Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
JP5820476B2 (en) | 2010-08-24 | 2015-11-24 | アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH | New use of leflunomide and malononitrile trilamide |
CN103298805A (en) | 2010-09-01 | 2013-09-11 | 埃姆比特生物科学公司 | Quinazoline compounds and methods of use thereof |
US20130225615A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
WO2012030913A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
EP2611809A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
US20130225614A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
WO2012030912A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
WO2012030944A2 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinoline and isoquinoline compounds and methods of use thereof |
JP5872558B2 (en) | 2010-09-01 | 2016-03-01 | アムビト ビオスシエンセス コルポラチオン | Pyrazolylaminoquinazoline hydrobromide |
US20130317045A1 (en) | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
EP2611502A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Adenosine a3 receptor modulating compounds and methods of use thereof |
WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
WO2012044641A1 (en) | 2010-09-29 | 2012-04-05 | Pathway Therapeutics Inc. | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
AU2011313906B2 (en) | 2010-10-11 | 2015-08-13 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide CCR3 antagonists |
CN103391784A (en) | 2010-10-15 | 2013-11-13 | 纽约市哥伦比亚大学理事会 | Obesity-related genes and their proteins and uses thereof |
LT2629776T (en) | 2010-10-18 | 2017-11-10 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
PT2632451T (en) | 2010-10-29 | 2017-12-14 | Algiax Pharmaceuticals Gmbh | Use of malononitrilamides in neuropathic pain |
WO2012064808A1 (en) | 2010-11-09 | 2012-05-18 | Synta Pharmaceuticals Corp | Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
WO2012078649A1 (en) | 2010-12-06 | 2012-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
WO2012078757A2 (en) | 2010-12-08 | 2012-06-14 | Synta Pharmaceuticals Corp. | Combination breast cancer therapy with hsp90 inhibitory compounds |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
US9532977B2 (en) | 2010-12-16 | 2017-01-03 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
ES2753198T5 (en) | 2010-12-16 | 2023-05-31 | Amgen Europe Gmbh | Oral pharmaceutical forms of controlled release of poorly soluble drugs and their uses |
AU2011346749A1 (en) | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof |
KR20140035331A (en) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | Chemosensory receptor ligand-based therapies |
EP2663549B1 (en) | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9757355B2 (en) | 2011-01-10 | 2017-09-12 | Celgene Corporation | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide |
US20130331357A1 (en) | 2011-01-11 | 2013-12-12 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
US8765760B2 (en) | 2011-01-11 | 2014-07-01 | Sunovion Pharmaceuticals, Inc. | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases |
US9045417B2 (en) | 2011-01-14 | 2015-06-02 | Celgene Corporation | Isotopologues of isoindole derivatives |
EP2665477B1 (en) | 2011-01-20 | 2015-09-09 | Bionevia Pharmaceuticals Inc. | Modified release compositions of epalrestat or a derivative thereof and methods for using the same |
WO2012106299A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
WO2012116061A1 (en) | 2011-02-23 | 2012-08-30 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
AU2012243289A1 (en) | 2011-02-24 | 2013-08-29 | Synta Pharmaceuticals Corp. | Prostate cancer therapy with Hsp90 inhibitory compounds |
WO2012116247A1 (en) | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
US9795792B2 (en) | 2011-02-25 | 2017-10-24 | Medtronic, Inc. | Emergency mode switching for non-pacing modes |
EP2683376B1 (en) | 2011-03-07 | 2018-11-28 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
US20120232159A1 (en) | 2011-03-07 | 2012-09-13 | Tonix Pharmaceuticals, Inc. | Methods and Compositions for Treating Depression using Cyclobenzaprine |
SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
EP2683384B1 (en) | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
WO2012123353A1 (en) | 2011-03-17 | 2012-09-20 | Algiax Pharmaceuticals Gmbh | Novel use of benzofuranylsulfonates |
US20140038967A1 (en) | 2011-03-17 | 2014-02-06 | Algiax Pharmaceuticals Gmbh | Novel use for imidazotriazinones |
WO2012129237A2 (en) | 2011-03-20 | 2012-09-27 | Trustees Of Boston University | Therapeutic agent for emphysema and copd |
EP2691389A1 (en) | 2011-03-28 | 2014-02-05 | MEI Pharma, Inc. | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
EP2691388A1 (en) | 2011-03-28 | 2014-02-05 | MEI Pharma, Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2012135160A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
WO2012158271A1 (en) | 2011-04-06 | 2012-11-22 | Anadys Pharmaceuticals, Inc. | Bridged polycyclic compounds as antiviral agents |
EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
JP5976100B2 (en) | 2011-04-21 | 2016-08-23 | キュアマーク リミテッド ライアビリティ カンパニー | Compounds for the treatment of neuropsychiatric disorders |
CN103635188B (en) | 2011-04-28 | 2017-03-22 | 细胞基因公司 | Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases |
WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US9604978B2 (en) | 2011-05-03 | 2017-03-28 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
US9480696B2 (en) | 2011-05-04 | 2016-11-01 | Trustees Of Boston University | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
EP2714038A1 (en) | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
JP2014522396A (en) | 2011-05-27 | 2014-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | Substituted 2-benzylidene-2H-benzo [b] [1,4] thiazin-3 (4H) -one, derivatives thereof and therapeutic use thereof |
CN103827100B (en) | 2011-06-07 | 2015-08-12 | 安那迪斯药品股份有限公司 | For reducing [1,2,4] thiadiazine 1,1-dioxide compound of serum uric acid |
RU2011122942A (en) | 2011-06-08 | 2012-12-20 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | NEW KINAZ INHIBITORS |
PT2723732T (en) | 2011-06-22 | 2017-02-17 | Purdue Pharma Lp | Trpv1 antagonists including dihydroxy substituent and uses thereof |
US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
CN103827113A (en) | 2011-06-23 | 2014-05-28 | Map药物公司 | Novel fluoroergoline analogs |
WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
AU2012280931A1 (en) | 2011-07-07 | 2014-02-27 | Synta Pharmaceuticals Corp. | Treating cancer with HSP90 inhibitory compounds |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
AR088218A1 (en) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS |
GB201112987D0 (en) | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
US9394293B2 (en) | 2011-08-10 | 2016-07-19 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
CN103930126A (en) | 2011-08-12 | 2014-07-16 | Bsrc亚历山大.弗莱明 | TNF superfamily trimerization inhibitors |
CA2844809A1 (en) | 2011-08-19 | 2013-02-28 | Synta Pharmaceuticals Corp. | Combination cancer therapy of hsp90 inhibitor with antimetabolite |
EP2959899B1 (en) | 2011-08-23 | 2017-02-22 | Cornerstone Therapeutics Inc. | Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TW201329096A (en) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
JP2014526474A (en) | 2011-09-12 | 2014-10-06 | アイディニックス ファーマシューティカルズ インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20130071394A1 (en) | 2011-09-16 | 2013-03-21 | John K. Troyer | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
JP2014526558A (en) | 2011-09-23 | 2014-10-06 | セルジーン コーポレイション | Romidepsin and 5-azacytidine for use in the treatment of lymphoma |
US20130244950A1 (en) | 2011-09-26 | 2013-09-19 | Celgene Corporation | Combination therapy for chemoresistant cancers |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
WO2013052776A1 (en) | 2011-10-07 | 2013-04-11 | Cedars-Sinai Medical Center | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties |
US20140271657A1 (en) | 2011-10-12 | 2014-09-18 | Children's Medical Center Corporation | Combinatorial compositions and methods of treating hemoglobinopathies |
WO2013056070A2 (en) | 2011-10-14 | 2013-04-18 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
TWI558401B (en) | 2011-11-01 | 2016-11-21 | 西建公司 | Methods for treating cancers using oral formulations of cytidine analogs |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
WO2013071049A1 (en) | 2011-11-10 | 2013-05-16 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
EP2797912B1 (en) | 2011-12-01 | 2016-05-25 | Purdue Pharma L.P. | Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
JP5946921B2 (en) | 2011-12-08 | 2016-07-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | Quaternized buprenorphine analogues |
CA2859173A1 (en) | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
WO2013095708A1 (en) | 2011-12-21 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel neuromodulatory compounds |
PT3130347T (en) | 2011-12-30 | 2019-12-10 | Halozyme Inc | Ph20 polypeptide variants, formulations and uses thereof |
DK2800578T3 (en) | 2012-01-05 | 2019-03-25 | Boston Medical Ct Corp | SLIT-ROBO SIGNAL FOR DIAGNOSIS AND TREATMENT OF Kidney Diseases |
KR20190120430A (en) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | Biguanide compositions and methods of treating metabolic disorders |
JP6175074B2 (en) | 2012-01-06 | 2017-08-02 | エルセリクス セラピューティクス インコーポレイテッド | Compositions and methods for treating metabolic disorders |
US10189825B2 (en) | 2012-02-08 | 2019-01-29 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
ES2671608T3 (en) | 2012-02-21 | 2018-06-07 | Celgene Corporation | Solid forms of 3- (4-nitro-1-oxoisoindolin-2-yl) piperidine-2,6-dione |
US20150018362A1 (en) | 2012-02-27 | 2015-01-15 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
WO2013130600A1 (en) | 2012-02-29 | 2013-09-06 | Ambit Biosciences Corporation | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith |
WO2013133708A1 (en) | 2012-03-07 | 2013-09-12 | Stichting Vu-Vumc | Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders |
CN104302640A (en) | 2012-03-16 | 2015-01-21 | 埃克希金医药品有限公司 | 3,5-diaminopyrazole kinase inhibitors |
ES2779698T3 (en) | 2012-03-19 | 2020-08-18 | Brigham & Womens Hospital Inc | Growth differentiation factor 11 (GDF) for the treatment of age-related cardiovascular conditions |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
US20140350087A9 (en) | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
WO2013148864A1 (en) | 2012-03-27 | 2013-10-03 | Andrei Gudkov | Curaxins for use in treating breast cancer and method for identifying patients likely to respond |
AU2013239663A1 (en) | 2012-03-28 | 2014-10-09 | Synta Pharmaceuticals Corp. | Triazole derivatives as HSP90 inhibitors |
PT2833905T (en) | 2012-04-04 | 2018-08-06 | Halozyme Inc | Combination therapy with hyaluronidase and a tumor-targeted taxane |
CA2868323A1 (en) | 2012-04-04 | 2013-10-10 | Synta Pharmaceuticals Corp. | Novel triazole compounds that modulate hsp90 activity |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013156231A1 (en) | 2012-04-16 | 2013-10-24 | Algiax Pharmaceuticals Gmbh | Use of imidazotriazinones in neuropathic pain |
WO2013156232A1 (en) | 2012-04-16 | 2013-10-24 | Algiax Pharmaceuticals Gmbh | Use of benzofuranylsulfonates in neuropathic pain |
CA3120681A1 (en) | 2012-04-17 | 2013-10-24 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
WO2013163758A1 (en) | 2012-05-01 | 2013-11-07 | Boyd Shelley Romayne | Methods for treating and diagnosing blinding eye diseases |
JP2015516439A (en) | 2012-05-10 | 2015-06-11 | シンタ ファーマシューティカルズ コーポレーション | Treating cancer with Hsp90-inhibiting compounds |
GB201208315D0 (en) | 2012-05-11 | 2012-06-27 | Numedicus Ltd | Pharmaceutical methods and compositions |
EP2858976B1 (en) | 2012-05-11 | 2018-03-14 | Purdue Pharma LP | Benzomorphan compounds as opioid receptors modulators |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
EP2861562B1 (en) | 2012-06-14 | 2018-05-09 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of stat3 |
JP6427097B2 (en) | 2012-06-15 | 2018-11-21 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Compositions for treating cancer and methods for producing said compositions |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
ES2699810T3 (en) | 2012-06-29 | 2019-02-12 | Celgene Corp | Methods to determine the efficacy of drugs using cereblon-associated proteins |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
JP2015522080A (en) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents |
US9034870B2 (en) | 2012-07-13 | 2015-05-19 | Purdue Research Foundation | Azaindenoisoquinoline topoisomerase I inhibitors |
US9085561B2 (en) | 2012-07-30 | 2015-07-21 | Purdue Pharma L.P. | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators |
WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
SG10201701057SA (en) | 2012-08-09 | 2017-03-30 | Celgene Corp | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
CN108938642A (en) | 2012-08-09 | 2018-12-07 | 细胞基因公司 | Immune related and inflammatory disease treatment |
CN104703978B (en) | 2012-08-09 | 2018-05-11 | 细胞基因公司 | Salt and solid form of compound and combinations thereof and application method |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
US10624859B2 (en) | 2012-08-20 | 2020-04-21 | Rhodes Technologies | Systems and methods for increasing stability of dronabinol compositions |
US9315514B2 (en) | 2012-08-27 | 2016-04-19 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
WO2014036528A2 (en) | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
AU2013312420A1 (en) | 2012-09-07 | 2015-02-26 | Axikin Pharmaceuticals, Inc. | Isotopically enriched arylsulfonamide CCR3 antagonists |
BR112015005243A2 (en) | 2012-09-10 | 2017-07-04 | Celgene Corp | Methods For Treating Locally Advanced Breast Cancer |
WO2014055647A1 (en) | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
EA030189B8 (en) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | 2'-chloro nucleoside analogs for hcv infection |
EP2906241B1 (en) | 2012-10-12 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
PT2914296T (en) | 2012-11-01 | 2018-10-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
CA2890177A1 (en) | 2012-11-08 | 2014-05-15 | Summa Health System | Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing |
JP2015536991A (en) | 2012-11-09 | 2015-12-24 | セルジーン コーポレイション | How to treat bone loss |
JP6400592B2 (en) | 2012-11-09 | 2018-10-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | Benzomorphan analogs and uses thereof |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
CA2889906A1 (en) | 2012-11-29 | 2014-06-05 | Sunovion Pharmaceuticals Inc. | Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system |
ES2689921T3 (en) | 2012-11-30 | 2018-11-16 | Novomedix, Llc | Substituted biarylsulfonamides and their uses |
WO2014087226A1 (en) | 2012-12-07 | 2014-06-12 | Purdue Pharma L.P. | Buprenorphine analogs as opiod receptor modulators |
ES2621305T3 (en) | 2012-12-14 | 2017-07-03 | Purdue Pharma Lp | Spirocyclic morphinans and their use |
US8980906B2 (en) | 2012-12-14 | 2015-03-17 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
TW201434836A (en) | 2012-12-14 | 2014-09-16 | Purdue Pharma Lp | Nitrogen containing morphinan derivatives and the use thereof |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
SG11201504931SA (en) | 2012-12-21 | 2015-07-30 | Map Pharmaceuticals Inc | Novel methysergide derivatives |
US9090618B2 (en) | 2012-12-27 | 2015-07-28 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
WO2014102590A1 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
WO2014102589A1 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Quinazolin-4(3h)-one-type piperidine compounds and uses thereof |
WO2014102588A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Indole and indoline-type piperidine compounds and uses thereof |
WO2014102592A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof |
JP6159416B2 (en) | 2012-12-28 | 2017-07-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | 7,8-cyclic morphinan analogs |
JP6159417B2 (en) | 2012-12-28 | 2017-07-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | Substituted morphinans and uses thereof |
CA2896871A1 (en) | 2012-12-31 | 2014-07-03 | Kerry L. Spear | Heterocyclic compounds and methods of use thereof |
SG11201505240QA (en) | 2013-01-05 | 2015-08-28 | Elcelyx Therapeutics Inc | Delayed-release composition comprising biguanide |
WO2014107745A1 (en) | 2013-01-07 | 2014-07-10 | Halozyme, Inc. | Metal sensitive mutants of matrix metalloproteases and uses thereof |
US9617607B2 (en) | 2013-01-08 | 2017-04-11 | Enzo Biochem, Inc. | Diagnosis and treatment of viral diseases |
WO2014110127A1 (en) | 2013-01-08 | 2014-07-17 | Enzo Biochem, Inc. | Diagnosis and treatment of viral diseases |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
CN104955483A (en) | 2013-01-30 | 2015-09-30 | 法莫斯医疗公司 | Treatments for depression and other diseases with a low dose agent |
EP2951160B1 (en) | 2013-01-31 | 2019-04-24 | Purdue Pharma LP | Benzomorphan analogs and the use thereof |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US9872854B2 (en) | 2013-03-14 | 2018-01-23 | Celgene Corporation | Methods for the treatment of psoriatic arthritis using apremilast |
WO2014143643A1 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California, A California Corporation | Acyclic nucleoside phosphonate diesters |
SG10201707528WA (en) | 2013-03-15 | 2017-10-30 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US8969358B2 (en) | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
AU2014248263A1 (en) | 2013-04-02 | 2015-10-15 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
JP2016518357A (en) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods and compositions for rejuvenating skeletal muscle stem cells |
DK3003309T3 (en) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Treatment of cancer with PI3 kinase isoform modulators |
WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
WO2014197835A2 (en) | 2013-06-06 | 2014-12-11 | The General Hospital Corporation | Methods and compositions for the treatment of cancer |
EP3881859B1 (en) | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
MX2015017123A (en) | 2013-06-14 | 2016-08-03 | Invictus Oncology Pvt Ltd | Lipid-based platinum compounds and nanoparticles. |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
ES2703623T3 (en) | 2013-06-28 | 2019-03-11 | Purdue Pharma Lp | Opioid antagonists for use in the treatment of arrhythmia induced by opioid analgesics |
TW201534726A (en) | 2013-07-03 | 2015-09-16 | Halozyme Inc | Thermally stable PH20 hyaluronidase variants and uses thereof |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
CA2924141C (en) | 2013-08-22 | 2022-06-07 | The General Hospital Corporation | 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase |
CA2922361C (en) | 2013-08-29 | 2022-07-12 | Trustees Of Boston University | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections |
CN105683182A (en) | 2013-08-30 | 2016-06-15 | 埃姆比特生物科学公司 | Biaryl acetamide compounds and methods of use thereof |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
US20160213659A1 (en) | 2013-09-24 | 2016-07-28 | George Sylvestre | Treatment of burn pain by trpv1 modulators |
WO2015051336A1 (en) | 2013-10-03 | 2015-04-09 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PE20160685A1 (en) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2928779A1 (en) | 2013-10-21 | 2015-04-30 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015065876A1 (en) | 2013-10-29 | 2015-05-07 | Thomas Jefferson University | Methods of prevention or treatment for pathologic thrombosis or inflammation |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
GB201319792D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
PL3068414T3 (en) | 2013-11-11 | 2021-08-30 | Naturex Inc. | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction |
EP3074039A4 (en) | 2013-11-26 | 2017-10-11 | The Brigham and Women's Hospital, Inc. | Compositions and methods for modulating an immune response |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
KR20160099090A (en) | 2013-11-27 | 2016-08-19 | 아이데닉스 파마슈티칼스 엘엘씨 | Nucleotides for the treatment of liver cancer |
DK3079712T3 (en) | 2013-12-11 | 2022-04-25 | Massachusetts Gen Hospital | USE OF MÜLLER INHIBITANT SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
JP6599334B2 (en) | 2013-12-20 | 2019-10-30 | ザ ジェネラル ホスピタル コーポレイション | Methods and assays for circulating tumor cells in the blood |
US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
WO2015097545A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
US9988392B2 (en) | 2013-12-26 | 2018-06-05 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
US9994571B2 (en) | 2013-12-26 | 2018-06-12 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
US9340542B2 (en) | 2013-12-26 | 2016-05-17 | Purdue Pharma L.P. | Propellane-based compounds and the use thereof |
US10550088B2 (en) | 2013-12-27 | 2020-02-04 | Purdue Pharma L.P. | 6-substituted and 7-substituted morphinan analogs and the use thereof |
EP3089978B1 (en) | 2013-12-30 | 2018-08-29 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
EP3096749B1 (en) | 2014-01-24 | 2019-05-15 | Celgene Corporation | Methods for the treatment of obesity using apremilast |
EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015138420A1 (en) | 2014-03-10 | 2015-09-17 | Kadmon Corporation, Llc | Treatment of brain and central nervous system tumors |
EP3119744B1 (en) | 2014-03-18 | 2019-03-06 | Algiax Pharmaceuticals GmbH | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives |
SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US11369588B2 (en) | 2014-03-20 | 2022-06-28 | The Trustees Of Princeton University | NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease |
US10202398B2 (en) | 2014-03-20 | 2019-02-12 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
CA2943220C (en) | 2014-03-20 | 2024-01-16 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
US20170107300A1 (en) | 2014-03-21 | 2017-04-20 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
AU2015241198A1 (en) | 2014-04-03 | 2016-11-17 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
WO2015153841A1 (en) | 2014-04-04 | 2015-10-08 | Ritter Pharmaceuticals, Inc. | Methods and compositions for microbiome alteration |
US10106549B2 (en) | 2014-04-09 | 2018-10-23 | Siteone Therapeutics, Inc. | 10′,11′-modified saxitoxins useful for the treatment of pain |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2015164364A2 (en) | 2014-04-25 | 2015-10-29 | The Brigham And Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
AU2015249666A1 (en) | 2014-04-25 | 2016-11-17 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating subjects with immune-mediated diseases |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
AU2015259471A1 (en) | 2014-05-12 | 2016-11-24 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with caspase inhibitors |
US9480676B2 (en) | 2014-05-15 | 2016-11-01 | Celgene Corporation | Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis |
EP3142663A1 (en) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
WO2015179366A1 (en) | 2014-05-19 | 2015-11-26 | Northeastern University | Serotonin receptor-targeting compounds and methods |
EP3145500A1 (en) | 2014-05-23 | 2017-03-29 | Sigmoid Pharma Limited | Celecoxib formulations useful for treating colorectal cancer |
JP2017516779A (en) | 2014-05-28 | 2017-06-22 | アイデニクス・ファーマシューティカルズ・エルエルシー | Nucleoside derivatives for cancer treatment |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
JP2017519000A (en) | 2014-06-12 | 2017-07-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Glucagon antagonist |
US20150359810A1 (en) | 2014-06-17 | 2015-12-17 | Celgene Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
US9527815B2 (en) | 2014-06-18 | 2016-12-27 | Biotheryx, Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases |
SI3157916T1 (en) | 2014-06-19 | 2019-05-31 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
ES2843973T3 (en) | 2014-06-27 | 2021-07-21 | Celgene Corp | Compositions and methods to induce conformational changes in cereblon and other E3 ubiquitin ligases |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
CN106794233B (en) | 2014-08-01 | 2021-11-12 | 布里格姆及妇女医院股份有限公司 | Compositions and methods relating to treatment of pulmonary hypertension |
WO2016025686A1 (en) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
PL3182996T3 (en) | 2014-08-22 | 2023-04-17 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
EP3186281B1 (en) | 2014-08-28 | 2019-04-10 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
CA2959386A1 (en) | 2014-08-29 | 2016-03-03 | Lee Adam Wheeler | Methods and compositions for the treatment of cancer |
SG10201902137PA (en) | 2014-09-12 | 2019-04-29 | Tobira Therapeutics Inc | Cenicriviroc combination therapy for the treatment of fibrosis |
KR102589658B1 (en) | 2014-09-15 | 2023-10-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Nucleotide analogs |
SG11201701995PA (en) | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
EP3194446B1 (en) | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
NZ730563A (en) | 2014-10-14 | 2019-05-31 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
TN2017000157A1 (en) | 2014-10-21 | 2018-10-19 | Ariad Pharma Inc | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine |
US20170354639A1 (en) | 2014-10-24 | 2017-12-14 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
KR20170102223A (en) | 2014-11-07 | 2017-09-08 | 시그모이드 파마 리미티드 | Compositions comprising cyclosporin |
TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
JP6707088B2 (en) | 2014-12-16 | 2020-06-10 | セルジーン コーポレイション | Solid form comprising (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide, composition thereof , And their use |
US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
CA2973978A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
BR112017015510A2 (en) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | compound of formula (i), method of treatment and / or prevention, d2 receptor agonizing method in one individual, d3 receptor antagonizing method in one individual, 5-ht1d receptor agonizing method in one individual, 5-ht1a receptor agonization in one individual, selective 5-ht1d receptor agonizing method instead of 5-ht1b receptor in one individual, 5-ht2c re-receptor selective agonizing method instead of 5-ht2a or 5 receptor -ht2b in one individual, method of 5-ht2c receptor agonization in one individual, method of providing functional antagonist activity at 5-ht2b receptor or 5-ht7 receptor, and, method of providing functional antagonist activity at adrenergic receptors in one individual |
US9657020B2 (en) | 2015-01-20 | 2017-05-23 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
CA2976072A1 (en) | 2015-02-09 | 2016-08-18 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer |
NZ735736A (en) | 2015-03-10 | 2019-02-22 | Rhodes Tech | Acetate salt of buprenorphine and methods for preparing buprenorphine |
TW201642857A (en) | 2015-04-06 | 2016-12-16 | 西建公司 | Treatment of hepatocellular carcinoma using combination therapy |
EP3285795B1 (en) | 2015-04-22 | 2022-11-16 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity |
US10253024B2 (en) | 2015-04-30 | 2019-04-09 | The Regents Of The University Of Colorado, A Body Corporate | Polycyclic indoline and indolenine compounds |
WO2016189055A1 (en) | 2015-05-27 | 2016-12-01 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of cancer |
WO2016196664A1 (en) | 2015-06-01 | 2016-12-08 | Cedars-Sinai Medical Center | Methods and use of compounds that bind to rela of nf-kb |
WO2016202721A1 (en) | 2015-06-16 | 2016-12-22 | F. Hoffmann-La Roche Ag | Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same |
KR20180015260A (en) | 2015-06-23 | 2018-02-12 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | VMAT2 inhibitors for the treatment of neurological diseases or disorders |
SI3313818T1 (en) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
EP3316888A1 (en) | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
RU2018107227A (en) | 2015-07-28 | 2019-08-28 | Виоме Терапьютикс Лимитед | THERAPEUTIC AND PREVENTIVE ANTIBACTERIAL MEANS |
WO2017023912A1 (en) | 2015-08-03 | 2017-02-09 | Temple University - Of The Commonwealth System Of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
DK3277842T5 (en) | 2015-08-17 | 2020-08-31 | Kura Oncology Inc | PROCEDURES FOR TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS |
CA2994729A1 (en) | 2015-08-27 | 2017-03-02 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
EP3347486A4 (en) | 2015-09-09 | 2019-06-19 | The Trustees of Columbia University in the City of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
EP3355909B1 (en) | 2015-09-28 | 2023-06-07 | Children's Hospital Los Angeles | Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages |
JP2018534270A (en) | 2015-09-30 | 2018-11-22 | サイトワン セラピューティクス, インコーポレイテッド | 11,13-modified saxitoxin for the treatment of pain |
KR20180051651A (en) | 2015-10-01 | 2018-05-16 | 히트 바이오로직스, 인코퍼레이티드 | Compositions and methods for adjacent I and II extracellular domains as heterologous chimeric proteins |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017064657A1 (en) | 2015-10-16 | 2017-04-20 | Invictus Oncology Pvt. Ltd. | Fluorescent anticancer platinum drugs |
CN115322188A (en) | 2015-10-30 | 2022-11-11 | 纽罗克里生物科学有限公司 | VALBENAZINE salts and polymorphs thereof |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
WO2017083348A1 (en) | 2015-11-11 | 2017-05-18 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
HUE059065T2 (en) | 2015-12-23 | 2022-10-28 | Neurocrine Biosciences Inc | Synthetic method for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
CN108697663A (en) | 2015-12-31 | 2018-10-23 | 科内图斯医药公司 | The method that caspase inhibitors are used in liver disease |
KR20180095094A (en) | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | The use of biomarkers as predictors of clinical susceptibility to treatment methods and therapies for cancer |
AR107320A1 (en) | 2016-01-08 | 2018-04-18 | Celgene Corp | SOLID FORMS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXOINDOLIN-5-IL) METHYL) -2,2-DIFLUOROACETAMIDE AND ITS PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS |
WO2017120422A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Antiproliferative compounds, and their pharmaceutical compositions and uses |
JP7166923B2 (en) | 2016-02-05 | 2022-11-08 | オリオニス バイオサイエンシズ ビーブイ | Targeted therapeutic agents and their uses |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
JP2019507762A (en) | 2016-03-07 | 2019-03-22 | ブイアイビー ブイゼットダブリュー | CD20 binding single domain antibody |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
EP3442940A1 (en) | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
US20190119758A1 (en) | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
ES2912921T3 (en) | 2016-04-29 | 2022-05-30 | Fgh Biotech Inc | Disubstituted pyrazole compounds for the treatment of diseases |
JP2019514960A (en) | 2016-05-04 | 2019-06-06 | パーデュー ファーマ エルピー | Oxazoline pseudodimer, pharmaceutical composition and use thereof |
US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
CN109563141A (en) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | To the therapeutic targeting of cellular structures |
TWI753910B (en) | 2016-05-16 | 2022-02-01 | 美商拜歐斯瑞克斯公司 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
FI3484475T3 (en) | 2016-07-18 | 2023-12-12 | Pharmena S A | 1-methylnicotinamide for the treatment of cardiovascular disease |
JOP20190008A1 (en) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | Treatment and prevention of sleep disorders |
CN116283877A (en) | 2016-07-29 | 2023-06-23 | 赛诺维信制药公司 | Compounds, compositions and uses thereof |
EA201990399A1 (en) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION |
EP3510027B1 (en) | 2016-09-07 | 2022-11-02 | FGH BioTech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
WO2018049019A1 (en) | 2016-09-07 | 2018-03-15 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of insulin resistance |
FR3055800B1 (en) * | 2016-09-15 | 2020-06-26 | Unither Pharmaceuticals | SOLID COMPOSITION WITH FAST INGESTION AND EASY SWALLOWING, IN THE FORM OF NON-AGGLOMERATED SOLID PARTICLES, COMPRISING TWO DIFFERENT TYPES OF PARTICLES |
JP2019529419A (en) | 2016-09-19 | 2019-10-17 | エムイーアイ ファーマ,インク. | Combination therapy |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US10918628B2 (en) | 2016-10-11 | 2021-02-16 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Treatment of synucleinopathies |
US11154591B2 (en) | 2016-10-14 | 2021-10-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating alcohol abuse disorder |
WO2018075993A1 (en) | 2016-10-21 | 2018-04-26 | Da Zen Theranostics, Inc | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors |
ES2917000T3 (en) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Target mutant interferon-gamma and uses thereof |
US11124839B2 (en) | 2016-11-03 | 2021-09-21 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
US10106521B2 (en) | 2016-11-09 | 2018-10-23 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
CN116987014A (en) | 2016-11-09 | 2023-11-03 | 诺沃梅迪科斯有限公司 | Nitrite salts of 1, 1-metformin, pharmaceutical compositions and methods of use |
US10799503B2 (en) | 2016-12-01 | 2020-10-13 | Ignyta, Inc. | Methods for the treatment of cancer |
TW202345829A (en) | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
JP7199361B2 (en) | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Methods for administering certain VMAT2 inhibitors |
WO2018140671A1 (en) | 2017-01-27 | 2018-08-02 | Celgene Corporation | 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
NZ753781A (en) | 2017-02-06 | 2022-10-28 | Spero Therapeutics Inc | Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use |
EP3580230A1 (en) | 2017-02-07 | 2019-12-18 | VIB vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
US11129807B2 (en) | 2017-02-16 | 2021-09-28 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
US10137121B2 (en) | 2017-02-21 | 2018-11-27 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
EP3432883B1 (en) | 2017-02-21 | 2021-07-28 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
AU2018224852A1 (en) | 2017-02-27 | 2019-07-11 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
WO2018165142A1 (en) | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
AU2018243463C1 (en) | 2017-03-29 | 2022-12-01 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
WO2018183782A1 (en) | 2017-03-29 | 2018-10-04 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
US20200179352A1 (en) | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
JOP20190219A1 (en) | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | Pharmaceutical compositions and methods of treating cardiovascular diseases |
US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
JP7212956B2 (en) | 2017-05-19 | 2023-01-26 | エヌフレクション セラピューティクス インコーポレイテッド | Pyrrolopyridine-aniline compounds for the treatment of skin disorders |
MA49140A (en) | 2017-05-19 | 2020-03-25 | Nflection Therapeutics Inc | MERGED HETEROAROMATIC-ANILINE COMPOUNDS FOR THE TREATMENT OF DERMAL DISORDERS |
EP3630079A4 (en) | 2017-05-31 | 2021-02-24 | The Children's Medical Center Corporation | TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA |
WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
WO2019005874A1 (en) | 2017-06-26 | 2019-01-03 | The Trustees Of Columbia University In The City Of New York | Cholinergic agonism for the treatment of pancreatic cancer |
US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
JP2020526592A (en) | 2017-07-13 | 2020-08-31 | トニックス ファーマシューティカルズ ホールディング コーポレーション | Cyclobenzaprine analogs and amitryptylene analogs |
WO2019018247A1 (en) | 2017-07-16 | 2019-01-24 | Neuere, Llc | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity |
EA202090414A1 (en) | 2017-08-02 | 2020-05-28 | Суновион Фармасьютикалз Инк. | COMPOUNDS AND THEIR APPLICATION |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
BR112020002591A2 (en) | 2017-08-07 | 2020-07-28 | Kura Oncology, Inc. | method for treating cancer |
CN111372567B (en) | 2017-09-21 | 2024-03-15 | 纽罗克里生物科学有限公司 | High dose valphenazine formulations and compositions, methods and kits relating thereto |
MX2020004071A (en) | 2017-10-02 | 2020-07-28 | Arixa Pharmaceuticals Inc | Aztreonam derivatives and uses thereof. |
SG11202003194YA (en) | 2017-10-10 | 2020-05-28 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
WO2019097080A1 (en) | 2017-11-20 | 2019-05-23 | Kiakos Konstantinos | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof |
WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
EP3723860A1 (en) | 2017-12-11 | 2020-10-21 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
CA3085593A1 (en) | 2017-12-18 | 2019-06-27 | Sterngreene, Inc. | Pyrimidine compounds useful as tyrosine kinase inhibitors |
US20190210973A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
US11701334B2 (en) | 2018-01-10 | 2023-07-18 | Cura Therapeutics, Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
TW201929847A (en) | 2018-01-10 | 2019-08-01 | 美商克拉治療有限責任公司 | Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications |
EP3743049A1 (en) | 2018-01-24 | 2020-12-02 | Purdue Pharma LP | Sleep disorder treatment and prevention |
MX2020008208A (en) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Fibroblast binding agents and use thereof. |
WO2019156565A1 (en) | 2018-02-12 | 2019-08-15 | Fast Forward Pharmaceuticals B.V. | Improved antagonistic anti-human cd40 monoclonal antibodies |
US20210008030A1 (en) | 2018-02-16 | 2021-01-14 | Sunovion Pharmaceuticals Inc. | Methods of treating social function disorders |
BR112020016256A2 (en) | 2018-02-21 | 2020-12-15 | AI Therapeutics, Inc. | COMBINATION THERAPY WITH APILIMOD AND GLUTEN-MATERIAL AGENTS |
EP3768299A1 (en) | 2018-03-22 | 2021-01-27 | The Children's Medical Center Corporation | Methods and compositions relating to lung repair |
US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
CN112638387A (en) | 2018-06-14 | 2021-04-09 | 纽罗克里生物科学有限公司 | VMAT2 inhibitor compounds, compositions, and methods related thereto |
WO2020006341A1 (en) | 2018-06-29 | 2020-01-02 | Conatus Pharmaceuticals, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
AU2019301699B2 (en) | 2018-07-11 | 2023-11-02 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
EP3836926A4 (en) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020047319A1 (en) | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
CA3114618C (en) | 2018-10-01 | 2023-09-05 | Arixa Pharmaceuticals, Inc. | Derivatives of relebactam and uses thereof |
WO2020072835A1 (en) | 2018-10-03 | 2020-04-09 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
EP3873469A2 (en) | 2018-11-01 | 2021-09-08 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
WO2020106308A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
US11572344B2 (en) | 2018-11-20 | 2023-02-07 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
CN113645964A (en) | 2018-11-20 | 2021-11-12 | 恩福莱克逊治疗有限公司 | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy |
JP2022513089A (en) | 2018-11-20 | 2022-02-07 | エヌフレクション セラピューティクス インコーポレイテッド | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer |
EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
EP3897638A1 (en) | 2018-12-21 | 2021-10-27 | Kura Oncology, Inc. | Therapies for squamous cell carcinomas |
US11447468B2 (en) | 2019-02-06 | 2022-09-20 | Dice Alpha, Inc. | IL-17 ligands and uses thereof |
CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
US20220142983A1 (en) | 2019-03-01 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2020181165A1 (en) | 2019-03-07 | 2020-09-10 | Conatus Pharmaceuticals Inc. | Caspase inhibitors and methods of use thereof |
CA3133071A1 (en) | 2019-03-12 | 2020-09-17 | Arixa Pharmaceuticals, Inc. | Crystalline form of an avibactam derivative |
AU2020236225A1 (en) | 2019-03-14 | 2021-09-16 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
TW202108170A (en) | 2019-03-15 | 2021-03-01 | 美商庫拉腫瘤技術股份有限公司 | Methods of treating cancer patients with farnesyltransferase inhibitors |
EP3712127A1 (en) | 2019-03-22 | 2020-09-23 | Deutsches Krebsforschungszentrum | Novel inhibitors of histone deacetylase 10 |
WO2020193431A1 (en) | 2019-03-22 | 2020-10-01 | Deutsches Krebsforschungszentrum | Novel inhibitors of histone deacetylase 10 |
JP2022527495A (en) | 2019-03-29 | 2022-06-02 | クラ オンコロジー, インコーポレイテッド | Treatment of squamous cell carcinoma with farnesyltransferase inhibitor |
TW202102218A (en) | 2019-04-01 | 2021-01-16 | 美商庫拉腫瘤技術股份有限公司 | Methods of treating cancer with farnesyltransferase inhibitors |
US20220257767A1 (en) | 2019-04-03 | 2022-08-18 | President And Fellows Of Harvard College | Ionic liquids for drug delivery |
US11565999B2 (en) | 2019-04-25 | 2023-01-31 | Arixa Pharmaceuticals, Inc. | Methods of synthesizing aztreonam derivatives |
WO2020223583A1 (en) | 2019-05-02 | 2020-11-05 | Kura Oncology, Inc. | Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors |
WO2020227437A1 (en) * | 2019-05-06 | 2020-11-12 | Axial Biotherapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
JP6890865B1 (en) | 2019-06-03 | 2021-06-18 | 株式会社大分大学先端医学研究所 | Cyclic amide compounds for the treatment of rabies and methods thereof |
EP3986163A2 (en) | 2019-06-19 | 2022-04-27 | Solarea Bio, Inc. | Microbial compositions and methods for producing upgraded probiotic assemblages |
CA3146157A1 (en) | 2019-07-11 | 2021-01-14 | Cura Therapeutics, Llc | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
EP3996813A1 (en) | 2019-07-11 | 2022-05-18 | Cura Therapeutics, LLC | Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications |
US11098002B2 (en) | 2019-07-26 | 2021-08-24 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease |
US11654124B2 (en) | 2019-07-29 | 2023-05-23 | Amneal Pharmaceuticals Llc | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
US10792262B1 (en) | 2019-07-29 | 2020-10-06 | Saol International Limited | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
WO2021038296A2 (en) | 2019-08-27 | 2021-03-04 | Tonix Pharma Holdings Limited | Modified tff2 polypeptides |
WO2021055376A1 (en) | 2019-09-16 | 2021-03-25 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
EP4034236A1 (en) | 2019-09-26 | 2022-08-03 | Abionyx Pharma SA | Compounds useful for treating liver diseases |
WO2021067335A1 (en) | 2019-10-01 | 2021-04-08 | Molecular Skin Therapeutics, Inc. | Benzoxazinone compounds as klk5/7 dual inhibitors |
BR112022009139A2 (en) | 2019-11-12 | 2022-09-06 | Actym Therapeutics Inc | IMMUNOSTIMULATING BACTERIA DISPENSING PLATFORMS AND THEIR USE FOR DISPENSING THERAPEUTIC PRODUCTS |
JP2023503899A (en) | 2019-11-22 | 2023-02-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Ionic liquids for drug delivery |
EP4069245A1 (en) | 2019-12-02 | 2022-10-12 | Celgene Corporation | Therapy for the treatment of cancer |
CN113367378A (en) * | 2020-03-09 | 2021-09-10 | 深圳波顿香料有限公司 | Preparation method of water blasting bead |
US20230093147A1 (en) | 2020-03-09 | 2023-03-23 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
TW202206062A (en) | 2020-04-24 | 2022-02-16 | 美國坦普大學 高等教育聯邦系統 | Methods for treatment of non-alcoholic steatohepatitis |
CN115996751A (en) | 2020-04-28 | 2023-04-21 | 哈佛大学校长及研究员协会 | Methods and compositions relating to ionic liquid adjuvants |
WO2021226033A1 (en) | 2020-05-07 | 2021-11-11 | President And Fellows Of Harvard College | Hyaluronic acid drug conjugates |
EP4157923A2 (en) | 2020-05-29 | 2023-04-05 | President And Fellows Of Harvard College | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes |
WO2021242970A1 (en) | 2020-05-29 | 2021-12-02 | Boulder Bioscience Llc | Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane |
EP4168414A1 (en) | 2020-06-18 | 2023-04-26 | Shy Therapeutics LLC | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
WO2021262579A1 (en) | 2020-06-23 | 2021-12-30 | President And Fellows Of Harvard College | Compositions and methods relating to combinatorial hyaluronic acid conjugates |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
CA3184852A1 (en) | 2020-07-10 | 2022-01-13 | Lida Katsimpardi | Use of gdf11 to diagnose and treat anxiety and depression |
CA3191433A1 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
IL300626A (en) | 2020-08-14 | 2023-04-01 | Siteone Therapeutics Inc | Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
TW202233173A (en) | 2020-10-30 | 2022-09-01 | 愛爾蘭商Ds生物製藥有限公司 | Pharmaceutical compositions comprising 15-hetre and methods of use thereof |
WO2022155410A1 (en) | 2021-01-15 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions relating to anti-mfsd2a antibodies |
WO2022161355A1 (en) | 2021-01-26 | 2022-08-04 | Cytocares (Shanghai) Inc. | Chimeric antigen receptor (car) constructs and nk cells expressing car constructs |
WO2022165000A1 (en) | 2021-01-27 | 2022-08-04 | Shy Therapeutics, Llc | Methods for the treatment of fibrotic disease |
EP4284377A1 (en) | 2021-01-27 | 2023-12-06 | Shy Therapeutics LLC | Methods for the treatment of fibrotic disease |
WO2022187573A1 (en) | 2021-03-05 | 2022-09-09 | President And Fellows Of Harvard College | Methods and compositions relating to cell membrane hybridization and camouflaging |
WO2022189010A1 (en) | 2021-03-07 | 2022-09-15 | Givaudan Sa | Methods and compositions for treating and preventing urinary tract infections |
WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
AU2022232625A1 (en) | 2021-03-10 | 2023-09-28 | Dice Molecules Sv, Inc. | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof |
CA3211496A1 (en) | 2021-03-19 | 2022-09-22 | Tiba Biotech Llc | Artificial alphavirus-derived rna replicon expression systems |
EP4326721A1 (en) | 2021-04-22 | 2024-02-28 | Protego Biopharma, Inc. | Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis |
EP4347568A1 (en) | 2021-05-27 | 2024-04-10 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
WO2022265880A1 (en) | 2021-06-16 | 2022-12-22 | President And Fellows Of Harvard College | Improved methods and compositions for drug delivery relating to ionic liquids |
WO2022271537A1 (en) | 2021-06-25 | 2022-12-29 | President And Fellows Of Harvard College | Compositions and methods relating to injectable microemulsions |
WO2023015240A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Tricyclic fused pyrimidine compounds for use as her2 inhibitors |
WO2023034507A1 (en) | 2021-09-01 | 2023-03-09 | Flagship Pioneering Innovations Vi, Llc | In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion |
WO2023034504A1 (en) | 2021-09-01 | 2023-03-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages |
WO2023034506A1 (en) | 2021-09-01 | 2023-03-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for inducing fetal hemoglobin |
US20230083717A1 (en) | 2021-09-01 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for promoting adipocyte beiging |
US20230077584A1 (en) | 2021-09-09 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating enteroendocrine cells |
WO2023039164A2 (en) | 2021-09-09 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating goblet cells and for muco-obstructive diseases |
WO2023043827A2 (en) | 2021-09-14 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for perturbing monocyte and neutrophil lineages |
WO2023055457A1 (en) | 2021-09-29 | 2023-04-06 | Amneal Pharmaceuticals Llc | Baclofen-containing granule formulations and reduced patient exposure to metabolite variations |
CA3233824A1 (en) | 2021-10-08 | 2023-04-13 | Samir Mitragotri | Ionic liquids for drug delivery |
EP4162933A1 (en) | 2021-10-08 | 2023-04-12 | Algiax Pharmaceuticals GmbH | Compound for treating non-alcoholic fatty liver disease and related diseases |
CA3235692A1 (en) | 2021-10-28 | 2023-05-04 | Zywie, Llc | Modified forms of ambroxol for therapeutic use |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
CA3234276A1 (en) | 2021-11-30 | 2023-06-08 | Kura Oncology, Inc. | Macrocyclic compounds having farnesyltransferase inhibitory activity |
US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
WO2023129577A1 (en) | 2022-01-03 | 2023-07-06 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
US20230303580A1 (en) | 2022-03-28 | 2023-09-28 | Isosterix, Inc. | Inhibitors of the myst family of lysine acetyl transferases |
US20230348909A1 (en) | 2022-03-30 | 2023-11-02 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
WO2023201282A1 (en) | 2022-04-14 | 2023-10-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
WO2023201348A1 (en) | 2022-04-15 | 2023-10-19 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
US20230416741A1 (en) | 2022-05-05 | 2023-12-28 | Biomarin Pharmaceutical Inc. | Method of treating duchenne muscular dystrophy |
WO2023230524A1 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vi, Llc | Compositions of secretory and/or catalytic cells and methods using the same |
WO2024054832A1 (en) | 2022-09-09 | 2024-03-14 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
WO2024073473A1 (en) | 2022-09-30 | 2024-04-04 | Boulder Bioscience Llc | Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU195492B (en) * | 1984-07-27 | 1988-05-30 | Boehringer Biochemia Srl | Process for producing 2-substituted thiazolidine derivatives with antitussive and mucus regulating action and pharmaceuticals comprising these compounds as active ingredient |
IT1216119B (en) * | 1988-03-17 | 1990-02-22 | Boehringer Biochemia Srl | BETA_CARBONIL_CARBOSSIAMIDI DI 1,3_TIAZOLIDINE. |
US5296236A (en) * | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
IT1226940B (en) * | 1988-09-16 | 1991-02-22 | Recordati Chem Pharm | THERAPEUTIC SYSTEM WITH CONTROLLED RELEASE FOR LIQUID PHARMACEUTICAL FORMULATIONS |
IT1264020B (en) * | 1993-01-28 | 1996-09-09 | Recordati Chem Pharm | PROCEDURE FOR THE PREPARATION OF MICROGRANULES SUITABLE FOR SUSPENSION IN LIQUIDS |
-
1994
- 1994-07-07 IT ITMI941410A patent/IT1270594B/en active IP Right Grant
-
1995
- 1995-05-26 US US08/452,435 patent/US5674533A/en not_active Expired - Fee Related
- 1995-05-29 HU HU9700017A patent/HUT76832A/en active IP Right Revival
- 1995-05-29 EP EP95918125A patent/EP0769948A1/en not_active Ceased
- 1995-05-29 WO PCT/IB1995/000412 patent/WO1996001628A1/en not_active Application Discontinuation
- 1995-05-29 CA CA002194374A patent/CA2194374A1/en not_active Abandoned
- 1995-05-29 JP JP8504206A patent/JPH10502629A/en active Pending
- 1995-05-29 MX MX9700223A patent/MX9700223A/en unknown
- 1995-05-29 AU AU24176/95A patent/AU2417695A/en not_active Abandoned
- 1995-05-29 CZ CZ199750A patent/CZ287967B6/en not_active IP Right Cessation
- 1995-05-29 BR BR9510302A patent/BR9510302A/en not_active Application Discontinuation
- 1995-05-29 KR KR1019970700062A patent/KR970704437A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ287967B6 (en) | 2001-03-14 |
ITMI941410A1 (en) | 1996-01-07 |
MX9700223A (en) | 1997-04-30 |
HUT76832A (en) | 1997-11-28 |
KR970704437A (en) | 1997-09-06 |
AU2417695A (en) | 1996-02-09 |
HU9700017D0 (en) | 1997-02-28 |
JPH10502629A (en) | 1998-03-10 |
BR9510302A (en) | 1997-11-11 |
EP0769948A1 (en) | 1997-05-02 |
IT1270594B (en) | 1997-05-07 |
US5674533A (en) | 1997-10-07 |
WO1996001628A1 (en) | 1996-01-25 |
CZ5097A3 (en) | 1997-09-17 |
ITMI941410A0 (en) | 1994-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2194374A1 (en) | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension | |
AU2001255509B2 (en) | Taste masking coating composition | |
US5405619A (en) | Controlled release therapeutic system for liquid pharmaceutical formulations | |
EP1276470B1 (en) | Taste masking coating composition | |
US5028664A (en) | Drug-release controlling coating material for long acting formulations | |
CZ284382B6 (en) | Solid medicament form with controlled release of active component | |
PL175569B1 (en) | Masked taste pharmaceutical preparations | |
AU2001255509A1 (en) | Taste masking coating composition | |
HRP20010463A2 (en) | Controlled release galantamine composition | |
EP0148811A1 (en) | Pharmaceutical composition | |
HRP20020119A2 (en) | Taste masked pharmaceutical liquid formulations | |
US20070003620A1 (en) | Morphine sulfate microgranules, method for preparing same and compositions containing same | |
EP0601508B1 (en) | Liquid-suspension controlled-release pharmaceutical composition | |
US7858118B2 (en) | Extended release composition containing Tramadol | |
CA2000932C (en) | Oral pharmaceutical controlled release multiple unit dosage form | |
JP2000500477A (en) | Immediate release pharmaceutical composition | |
JP2000256195A (en) | Nifedipine pill and preparation of nifedipine pill | |
ES2288600T3 (en) | FILM COATINGS WITH CONTROLLED RELEASE AND HIGH STABILITY. | |
RU2117476C1 (en) | Ranitidine tablet covered by hydroxypropylmethylcellulose and a method of cover applying | |
US5258186A (en) | Drug release controlling coating material for long acting formulations | |
MXPA94005567A (en) | Controlled release systems for the pharmacotacrine and methods to prepare |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |